

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 June 2003 (12.06.2003)

PCT

(10) International Publication Number
WO 03/047583 A1

(51) International Patent Classification⁷: **A61K 31/4709**,
A61P 35/00

[GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number: PCT/GB02/05497

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(22) International Filing Date: 5 December 2002 (05.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01403126.4 5 December 2001 (05.12.2001) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except MG, US*): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **HENNEQUIN, Laurent, Francois, Andre** [FR/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **GIBSON, Keith, Hopkinson** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **FOOTE, Kevin, Michael**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS



(57) Abstract: The invention concerns the use of quinoline derivatives of Formula (I) wherein each of Z, m, R¹, n and R³ have any of the meanings defined hereinbefore in the description in the manufacture of a medicament for use for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

WO 03/047583 A1

46 x 2

PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED
3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS

The invention concerns a new use of certain quinoline derivatives, or pharmaceutically-acceptable salts thereof, which have been found to possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body, for example in the manufacture of medicaments for use in the prevention or treatment of solid tumour disease in warm-blooded animals such as man.

Cancer is a disease in which cells grow and divide in an uncontrolled fashion. This uncontrolled growth arises from abnormalities in signal transduction pathways that are used by normal cells to regulate cell growth and division in response to various signalling molecules. Normal cells do not proliferate unless stimulated to do so by specific signal molecules located outside the cell derived from nearby cells or tissues. Growth factors bind to the cell membrane via specific receptors which have intrinsic enzyme activity. These receptors relay the growth signal to the cell nucleus via a series of signalling proteins. In cancer, a number of defects in signal pathways are apparent. For example, cancer cells may produce their own growth factors which bind to their cognate receptors, resulting in an autocrine loop, or receptors may be mutated or overexpressed leading to an increased, continuous signal to proliferate. In addition, negative regulators of cell growth may be lost.

Oncogenes are cancer related genes which often encode abnormal versions of signal pathway components, such as receptor tyrosine kinases, serine-threonine kinases, or downstream signaling molecules such as the ras genes, which code for closely related small guanine nucleotide binding proteins which hydrolyse bound guanosine triphosphate (GTP) to guanosine diphosphate (GDP). Ras proteins are active in promoting cell growth and transformation when they are bound to GTP and inactive when they are bound to GDP. Transforming mutants of p21ras are defective in their GTPase activity and hence remain in the active GTP bound state. The ras oncogene is known to play an integral role in certain cancers, and has been found to contribute to the formation of over 20% of all cases of human cancer.

When activated by ligand, cell surface receptors which are coupled to the mitogenic response, such as growth factor receptors, initiate a chain of reactions which leads to the activation of guanine nucleotide exchange activity on ras. When in its active GTP-bound state, a number of proteins interact directly with ras at the plasma membrane resulting in signal transmission through several distinct pathways. The best characterised effector protein is the

- 2 -

product of the raf proto-oncogene. The interaction of raf and ras is a key regulatory step in the control of cell proliferation. Ras-mediated activation of the raf serine-threonine kinase in turn activates the dual-specificity MEK (MEK1 and MEK2), which is the immediate upstream activator of mitogen activated protein kinase (MAPKs known as extracellular signal regulated protein kinases or ERK1 and ERK2). To date, no substrates of MEK other than MAPK have been identified, though recent reports indicate that MEK may also be activated by other upstream signal proteins such as MEKK1 and Cot/Tpl-2. Activated MAPK translocates and accumulates in the nucleus, where it can phosphorylate and activate transcription factors such as Elk-1 and Sap1a, leading to the enhanced expression of genes such as that for c-fos.

10 The ras-dependent raf-MEK-MAPK cascade is one of the key signalling pathways responsible for transmitting and amplifying mitogenic signals from cell surface to the nucleus resulting in changes in gene expression and cell fate. This ubiquitous pathway appears essential for normal cell proliferation and constitutive activation of this pathway is sufficient to induce cellular transformation. Transforming mutants of p21ras are constitutively active, resulting in raf, MEK and MAPK activity and cell transformation. Inhibition of MEK activity using either antisense raf, a dominant negative MEK mutant or the selective inhibitor PD098059 have been shown to block the growth and morphological transformation of ras-transformed fibroblasts.

20 The mechanism of activation of raf, MEK and MAPK is through phosphorylation on specific serine, threonine or tyrosine residues. Activated raf and other kinases phosphorylate MEK1 on S218 and S222 and MEK2 on S222 and S226. This results in MEK activation and subsequent phosphorylation and activation of ERK1 on T190 and Y192 and ERK2 on T183 and Y185 by the dual specificity MEKs. Whilst MEK can be activated by a number of protein kinases, and active MAPKs phosphorylate and activate a number of substrate proteins including transcription factors and other protein kinases, MEKs appear specific and sole activators of MAPKs and could act as a focal point for cross-cascade regulation. MEK1 and MEK2 isoforms show unusual specificity and also contain a proline-rich insert between catalytic subdomains IX and X which is not present in any of the other known MEK family members. These differences between MEK and other protein kinases, together with the known role of MEK (MEK 1, MEK 2) and, more recently, MEK 5 in proliferative signalling suggest that it may be possible to discover and employ selective MEK inhibitors as therapeutic agents for use in proliferative disease.


- 3 -

It is stated in International Patent Application WO 98/43960 that a range of 3-cyanoquinoline derivatives are useful in the treatment of cancer. Certain of the compounds are stated to be inhibitors of EGF receptor tyrosine kinase, others are stated to be inhibitors of the mitogen-activated protein kinase (MAPK) pathway and others are stated to be inhibitors of growth factors such as vascular endothelial growth factor (VEGF). There is no disclosure therein of any 4-benzofuranylamino-3-cyanoquinoline derivatives.

It is stated in International Patent Application WO 00/68201 that a range of 3-cyanoquinoline derivatives are also useful in the treatment of cancer. Certain of the compounds are stated to be inhibitors of MEK, a MAPK kinase. There is no disclosure therein of any 4-benzofuranylamino-3-cyanoquinoline derivatives.

It is also stated in International Patent Application WO 00/18761 that a range of 3-cyanoquinoline derivatives are also useful in the treatment of cancer. Certain of the compounds are stated to be inhibitors of MEK, a MAPK kinase. There is no disclosure therein of any 4-benzofuranylamino-3-cyanoquinoline derivatives.

According to one aspect of the invention there is provided the use of a quinoline derivative of the Formula I



wherein Z is an O, S, SO, SO₂, N(R²) or C(R²)₂ group, wherein each R² group, which may be the same or different, is hydrogen or (1-6C)alkyl;

m is 0, 1, 2, 3 or 4;

each R¹ group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino,

- 4 -

N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein X^1 is a direct bond or is selected from O, S, SO, SO₂, N(R⁴), CO, CH(OR⁴), CON(R⁴), N(R⁴)CO, SO₂N(R⁴), N(R⁴)SO₂, OC(R⁴)₂, SC(R⁴)₂ and N(R⁴)C(R⁴)₂, wherein R⁴ is hydrogen or (1-6C)alkyl, and Q¹ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-

10 (1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R¹)_m is (1-3C)alkylenedioxy, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R⁵), CO, CH(OR⁵), CON(R⁵), N(R⁵)CO, SO₂N(R⁵), N(R⁵)SO₂, CH=CH and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl or, when the inserted group is N(R⁵), R⁵ may also be

15 (2-6C)alkanoyl,

and wherein any CH₂=CH- or HC≡C- group within a R¹ substituent optionally bears at the terminal CH₂= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or

20 from a group of the formula :




wherein X^2 is a direct bond or is selected from CO and N(R⁶)CO, wherein R⁶ is hydrogen or (1-6C)alkyl, and Q² is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

25 and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, 30 (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl,

- 5 -

(1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




wherein X^3 is a direct bond or is selected from O, S, SO, SO₂, N(R⁷), CO, CH(OR⁷),

- 5 CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, C(R⁷)₂O, C(R⁷)₂S and N(R⁷)C(R⁷)₂, wherein R⁷ is hydrogen or (1-6C)alkyl, and Q³ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹

- 10 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,
- 15 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



- 20 wherein X^4 is a direct bond or is selected from O and N(R⁹), wherein R⁹ is hydrogen or (1-6C)alkyl, and R⁸ is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or from a group of the formula :

- 25 $-X^5-Q^4$

wherein X^5 is a direct bond or is selected from O, N(R¹⁰) and CO, wherein R¹⁰ is hydrogen or (1-6C)alkyl, and Q⁴ is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and


- 30 (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo or thioxo substituents;


- 6 -

n is 0, 1, 2 or 3; and

R^3 is halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X^6 is a direct bond or is selected from O and N(R^{12}), wherein R^{12} is hydrogen or (1-6C)alkyl, and R^{11} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



wherein X^7 is a direct bond or is selected from O, S, SO, SO₂, N(R^{13}), CO, CH(OR¹³), CON(R^{13}), N(R^{13})CO, SO₂N(R^{13}), N(R^{13})SO₂, C(R^{13})₂O, C(R^{13})₂S and N(R^{13})C(R^{13})₂, wherein R^{13} is hydrogen or (1-6C)alkyl, and Q^5 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy, and any heterocyclyl group within Q^5 optionally bears 1 or 2 oxo or thioxo substituents, or a pharmaceutically-acceptable salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

According to a further feature of the invention there is provided a method for producing an anti-proliferative effect by the containment and/or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

- 7 -

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or treatment of those tumours which are sensitive to inhibition of MEK enzymes that are involved in the MAPK pathway. Particular enzymes that the tumours may be sensitive to are MEK 1, MEK 2 and MEK 5.

According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of those tumours which are sensitive to inhibition of MEK enzymes that are involved in the MAPK pathway which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided the use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in providing a MEK enzyme inhibitory effect.

According to a further feature of this aspect of the invention there is provided a method for providing a MEK enzyme inhibitory effect which comprises administering to said animal an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.

According to a further aspect of the invention there is provided a novel quinoline derivative of Formula I, as hereinbefore defined, where Z, m and R¹ are as hereinbefore defined, n is 1, 2 or 3 and at least one R³ is formyl, or a pharmaceutically-acceptable salt.

In this specification the generic term "alkyl" includes both straight-chain and branched-chain alkyl groups such as propyl, isopropyl and tert-butyl, and also (3-7C)cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only, references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only and references to individual cycloalkyl groups such as "cyclopentyl" are specific for that 5-membered ring only. An analogous convention applies to other generic terms, for example (1-6C)alkoxy includes methoxy, ethoxy, cyclopropyloxy and cyclopentyloxy, (1-6C)alkylamino includes methylamino, ethylamino, cyclobutylamino and cyclohexylamino, and di-[(1-6Calkyl)]amino

- 8 -

includes dimethylamino, diethylamino, N-cyclobutyl-N-methylamino and N-cyclohexyl-N-ethylamino.

It is to be understood that, insofar as certain of the compounds of Formula I defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.

Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

Suitable values for the generic radicals referred to above include those set out below.

A suitable value for any one of the 'Q' groups (Q^1 to Q^5) when it is aryl or for the aryl group within a 'Q' group is, for example, phenyl or naphthyl, preferably phenyl.

A suitable value for any one of the 'Q' groups (Q^1 or Q^3) when it is (3-7C)cycloalkyl or for the (3-7C)cycloalkyl group within a 'Q' group is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl and a suitable value for any one of the 'Q' groups (Q^1 or Q^3) when it is (3-7C)cycloalkenyl or for the (3-7C)cycloalkenyl group within a 'Q' group is, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl.

A suitable value for any one of the 'Q' groups (Q^1 to Q^5) when it is heteroaryl or for the heteroaryl group within a 'Q' group is, for example, an aromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl.

A suitable value for any one of the 'Q' groups (Q^1 to Q^5) when it is heterocyclyl or for the heterocyclyl group within a 'Q' group is, for example, a non-aromatic saturated or partially saturated 3 to 10 membered monocyclic or bicyclic ring with up to five heteroatoms selected from oxygen, nitrogen and sulphur, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, tetrahydrothienyl, 1,1-dioxotetrahydrothienyl,

- 9 -

tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, azetidiny, pyrroliny, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, 1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, preferably tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, 1,1-dioxotetrahydro-4H-1,4-thiazinyl, piperidinyl or piperazinyl. A suitable value for such a group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

A suitable value for a 'Q' group when it is heteroaryl-(1-6C)alkyl is, for example, heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl. The invention comprises corresponding suitable values for 'Q' groups when, for example, rather than a heteroaryl-(1-6C)alkyl group, an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group is present.

In structural Formula I there is a hydrogen atom at the 2-position on the quinoline ring. It is to be understood thereby that the R¹ substituents may only be located at the 5-, 6-, 7- or 8-positions on the quinoline ring *i.e.* that the 2-position remains unsubstituted. It is further to be understood that the R³ group that may be present on the benzofuranyl group within structural Formula I may be located on either the 5- or 6-membered ring portions thereof, for example at the 2-, 3-, 4-, 5- or 6-positions of the benzofuran-7-yl group. It is to be further understood that, when multiple R³ groups are present, the R³ groups may be the same or different.

Suitable values for any of the 'R' groups (R¹ to R¹³) or for various groups within an R¹ or R³ substituent include :-

for halogeno	fluoro, chloro, bromo and iodo;
for (1-6C)alkyl:	methyl, ethyl, propyl, isopropyl and <u>tert</u> -butyl;
for (2-8C)alkenyl:	vinyl, isopropenyl, allyl and but-2-enyl;
for (2-8C)alkynyl:	ethynyl, 2-propynyl and but-2-ynyl;
for (1-6C)alkoxy:	methoxy, ethoxy, propoxy, isopropoxy and butoxy;
for (2-6C)alkenyloxy:	vinylloxy and allyloxy;
for (2-6C)alkynyloxy:	ethynyloxy and 2-propynyloxy;
for (1-6C)alkylthio:	methylthio, ethylthio and propylthio;
for (1-6C)alkylsulphinyl:	methylsulphinyl and ethylsulphinyl;

- 10 -

- for (1-6C)alkylsulphonyl: methylsulphonyl and ethylsulphonyl;
- for (1-6C)alkylamino: methylamino, ethylamino, propylamino, isopropylamino and butylamino;
- for di-[(1-6C)alkyl]amino: dimethylamino, diethylamino, N-ethyl-
5 N-methylamino and diisopropylamino;
- for (1-6C)alkoxycarbonyl: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and tert-butoxycarbonyl;
- for N-(1-6C)alkylcarbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl;
- 10 for N,N-di-[(1-6C)alkyl]carbamoyl: N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl and N,N-diethylcarbamoyl;
- for (2-6C)alkanoyl: acetyl and propionyl;
- for (2-6C)alkanoyloxy: acetoxyl and propionyloxy;
- for (2-6C)alkanoylamino: acetamido and propionamido;
- 15 for N-(1-6C)alkyl-(2-6C)alkanoylamino: N-methylacetamido and N-methylpropionamido;
- for N-(1-6C)alkylsulphamoyl: N-methylsulphamoyl and N-ethylsulphamoyl;
- for N,N-di-[(1-6C)alkyl]sulphamoyl: N,N-dimethylsulphamoyl;
- for (1-6C)alkanesulphonylamino: methanesulphonylamino and ethanesulphonylamino;
- for N-(1-6C)alkyl-(1-6C)alkanesulphonylamino: N-methylmethanesulphonylamino and
20 N-methylethanesulphonylamino;
- for (3-6C)alkenoylamino: acrylamido, methacrylamido and crotonamido;
- for N-(1-6C)alkyl-(3-6C)alkenoylamino: N-methylacrylamido and N-methylcrotonamido;
- for (3-6C)alkynoylamino: propiolamido;
- for N-(1-6C)alkyl-(3-6C)alkynoylamino: N-methylpropiolamido;
- 25 for amino-(1-6C)alkyl: aminomethyl, 2-aminoethyl, 1-aminoethyl and 3-aminopropyl;
- for (1-6C)alkylamino-(1-6C)alkyl: methylaminomethyl, ethylaminomethyl, 1-methylaminoethyl, 2-methylaminoethyl, 2-ethylaminoethyl and 3-methylaminopropyl;
- 30 for di-[(1-6C)alkyl]amino-(1-6C)alkyl: dimethylaminomethyl, diethylaminomethyl, 1-dimethylaminoethyl, 2-dimethylaminoethyl and 3-dimethylaminopropyl;

- 11 -

- for halogeno-(1-6C)alkyl: chloromethyl, 2-chloroethyl, 1-chloroethyl and 3-chloropropyl;
- for hydroxy-(1-6C)alkyl: hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and 3-hydroxypropyl;
- 5 for (1-6C)alkoxy-(1-6C)alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl and 3-methoxypropyl;
- for cyano-(1-6C)alkyl: cyanomethyl, 2-cyanoethyl, 1-cyanoethyl and 3-cyanopropyl;
- 10 for (2-6C)alkanoylamino-(1-6C)alkyl: acetamidomethyl, propionamidomethyl and 2-acetamidoethyl; and
- for (1-6C)alkoxycarbonylamino-(1-6C)alkyl: methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl, tert-butoxycarbonylaminomethyl and
- 15 2-methoxycarbonylaminoethyl.

A suitable value for $(R^1)_m$ when it is a (1-3C)alkylenedioxy group is, for example, methylenedioxy or ethylenedioxy and the oxygen atoms thereof occupy adjacent ring positions.

When, as defined hereinbefore, an R^1 group forms a group of the formula Q^1-X^1 - and, for example, X^1 is a $OC(R^4)_2$ linking group, it is the carbon atom, not the oxygen atom, of the $OC(R^4)_2$ linking group which is attached to the quinoline ring and the oxygen atom is attached to the Q^1 group. Similarly, when, for example a CH_3 group within a R^1 substituent bears a group of the formula $-X^3-Q^3$ and, for example, X^3 is a $C(R^7)_2O$ linking group, it is the carbon atom, not the oxygen atom, of the $C(R^7)_2O$ linking group which is attached to the CH_3 group and the oxygen atom is linked to the Q^3 group. A similar convention applies to the attachment of the groups of the formulae Q^2-X^2 - and $-X^7-Q^5$.

As defined hereinbefore, adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent may be optionally separated by the insertion into the chain of a group such as O, $CON(R^5)$ or $C\equiv C$. For example, insertion of a $C\equiv C$ group into the ethylene chain within a 2-morpholinoethoxy group gives rise to a 4-morpholinobut-2-ynyloxy group and, for example, insertion of a CONH group into the ethylene chain within a 3-methoxypropoxy group gives rise to, for example, a 2-(2-methoxyacetamido)ethoxy group.

- 12 -

When, as defined hereinbefore, any $\text{CH}_2=\text{CH}-$ or $\text{HC}\equiv\text{C}-$ group within a R^1 substituent optionally bears at the terminal $\text{CH}_2=$ or $\text{HC}\equiv$ position a substituent such as a group of the formula Q^2-X^2 - wherein X^2 is, for example, NHCO and Q^2 is a heterocyclyl-(1-6C)alkyl group, suitable R^1 substituents so formed include, for example, N-[heterocyclyl-

5 (1-6C)alkyl]carbamoylethynyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylethynyl or N-[heterocyclyl-(1-6C)alkyl]carbamoylethynyl groups such as N-(2-pyrrolidin-1-ylethyl)carbamoylethynyl.

When, as defined hereinbefore, any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl

10 substituents, there are suitably 1 or 2 halogeno or (1-6C)alkyl substituents present on each said CH_2 group and there are suitably 1, 2 or 3 such substituents present on each said CH_3 group.

When, as defined hereinbefore, any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group a substituent as defined hereinbefore, suitable R^1 substituents so formed include, for example, hydroxy-substituted heterocyclyl-

15 (1-6C)alkoxy groups such as 2-hydroxy-3-piperidinopropoxy and 2-hydroxy-3-morpholinopropoxy, hydroxy-substituted amino-(2-6C)alkoxy groups such as 3-amino-2-hydroxypropoxy, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkoxy groups such as 2-hydroxy-3-methylaminopropoxy, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkoxy groups such as 3-dimethylamino-2-hydroxypropoxy, hydroxy-substituted heterocyclyl-

20 (1-6C)alkylamino groups such as 2-hydroxy-3-piperidinopropylamino and 2-hydroxy-3-morpholinopropylamino, hydroxy-substituted amino-(2-6C)alkylamino groups such as 3-amino-2-hydroxypropylamino, hydroxy-substituted (1-6C)alkylamino-(2-6C)alkylamino groups such as 2-hydroxy-3-methylaminopropylamino, hydroxy-substituted di-[(1-6C)alkyl]amino-(2-6C)alkylamino groups such as 3-dimethylamino-

25 2-hydroxypropylamino, hydroxy-substituted (1-6C)alkoxy groups such as 2-hydroxyethoxy, (1-6C)alkoxy-substituted (1-6C)alkoxy groups such as 2-methoxyethoxy and 3-ethoxypropoxy, (1-6C)alkylsulphonyl-substituted (1-6C)alkoxy groups such as 2-methylsulphonylethoxy and heterocyclyl-substituted (1-6C)alkylamino-(1-6C)alkyl groups such as 2-morpholinoethylaminomethyl, 2-piperazin-1-ylethylaminomethyl and

30 3-morpholinopropylaminomethyl.


A suitable pharmaceutically-acceptable salt of a compound of the Formula I for use according to the invention is, for example, an acid-addition salt of a compound of the Formula

- 13 -

I, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the Formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

Particular compounds of Formula I or pharmaceutically acceptable salts thereof for use according to the invention include, for example, quinoline derivatives of the Formula I, wherein, unless otherwise stated, each of Z, m, R¹, n and R³ has any of the meanings defined hereinbefore or in paragraphs (a) to (q) hereinafter :-

- (a) Z is O, S, SO, SO₂, CH₂ or NH;
- (b) Z is O;
- (c) Z is NH;
- (d) m is 1 or 2, and each R¹ group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino and N-(1-6C)alkyl-(3-6C)alkynoylamino, or from a group of the formula :



wherein X¹ is a direct bond or is selected from O, N(R⁴), CON(R⁴), N(R⁴)CO and OC(R⁴)₂

wherein R⁴ is hydrogen or (1-6C)alkyl, and Q¹ is aryl, aryl-(1-6C)alkyl, cycloalkyl-


(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, N(R⁵), CON(R⁵), N(R⁵)CO, CH=CH and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl, or, when the inserted group is N(R⁵), R⁵ may also be (2-6C)alkanoyl,

- and wherein any CH₂=CH- or HC≡C- group within a R¹ substituent optionally bears at the terminal CH₂= or HC≡ position a substituent selected from carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl,

- 14 -

(1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :




wherein X^2 is a direct bond or is CO or $N(R^6)CO$, wherein R^6 is hydrogen or (1-6C)alkyl, and

5 Q^2 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno groups or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyloxy, (2-6C)alkanoylamino and \underline{N} -(1-6C)alkyl-(2-6C)alkanoylamino, or from a

10 group of the formula :




wherein X^3 is a direct bond or is selected from O, $N(R^7)$, $CON(R^7)$, $N(R^7)CO$ and $C(R^7)_2O$,

wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,


15 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, \underline{N} -(1-6C)alkylcarbamoyl, $\underline{N,N}$ -di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected

20 from a group of the formula :



wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl,

25 (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the formula :




wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2

30 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

- 15 -

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents;

- (e) m is 1 or 2, and each R¹ group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, butyl, vinyl, allyl, but-3-enyl, pent-4-enyl, hex-5-enyl, ethynyl, 2-propynyl, but-3-ynyl, pent-4-ynyl, hex-5-ynyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, allyloxy, but-3-enyloxy, pent-4-enyloxy, hex-5-enyloxy, ethynyloxy, 2-propynyloxy, but-3-ynyloxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, propionamido, acrylamido and propiolamido, or from a group of the formula :



- wherein X¹ is a direct bond or is selected from O, NH, CONH, NHCO and OCH₂ and Q¹ is phenyl, benzyl, cyclopropylmethyl, 2-thienyl, 1-imidazolyl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 2-, 3- or 4-pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, 2-(1,2,4-triazolyl)ethyl, 3-(1,2,4-triazolyl)propyl, 2-, 3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3- or 4-pyridyl)propyl, tetrahydrofuran-3-yl, 3- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,


- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CONH, NHCO, CH=CH and C≡C,

- 16 -

and wherein any $\text{CH}_2=\text{CH}-$ or $\text{HC}\equiv\text{C}-$ group within a R^1 substituent optionally bears at the terminal $\text{CH}_2=$ or $\text{HC}\equiv$ position a substituent selected from carbamoyl,

N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N-dimethylcarbamoyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, methylaminomethyl,

- 5 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl or 4-dimethylaminobutyl, or from a group of the formula :




wherein X^2 is a direct bond or is CO, NHCO or N(Me)CO and Q^2 is pyridyl, pyridylmethyl,

- 10 2-pyridylethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 15 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro or chloro groups or a substituent selected from

- 20 hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxy, acetamido and N-methylacetamido or from a group of the formula :




wherein X^3 is a direct bond or is selected from O, NH, CONH, NHCO and CH_2O and Q^3 is

- 25 pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-30 1-ylpropyl,


and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from

- 17 -

fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula :



- 5 wherein X^4 is a direct bond or is selected from O and NH and R^8 is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl, methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl, and from a group of the formula :



- wherein X^5 is a direct bond or is selected from O, NH and CO and Q^4 is pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,
- and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2
- 20 oxo substituents; and
- (f) m is 1 and the R^1 group is located at the 5-, 6- or 7-position or m is 2 and each R^1 group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R^1 is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, vinyl, ethynyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, but-3-enyloxy, pent-4-enyloxy, hex-5-enyloxy, but-3-ynyloxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, pyrrolidin-1-yl, piperidino, cyclopentyloxy, cyclohexyloxy, phenoxy, benzyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, cyclopropylmethoxy, 2-imidazol-1-ylethoxy, 3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, 2-(1,2,4-triazol-1-yl)ethoxy, 3-(1,2,4-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, pyrid-4-ylmethoxy, 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy, 3-pyrid-3-ylpropoxy,

- 18 -


- 3-pyrid-4-ylpropoxy, pyrrolidin-1-yl, morpholino, piperidino, piperazin-1-yl,
 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy,
 pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,
 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,
 5 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy,
 piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy,
 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy,
 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,
 10 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy,
 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy, 2-pyrrolidin-1-ylethylamino,
 3-pyrrolidin-1-ylpropylamino, 4-pyrrolidin-1-ylbutylamino, pyrrolidin-3-ylamino,
 pyrrolidin-2-ylmethylanino, 2-pyrrolidin-2-ylethylamino, 3-pyrrolidin-2-ylpropylamino,
 2-morpholinoethylamino, 3-morpholinopropylamino, 4-morpholinobutylamino,
 15 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino, 3-(1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-yl)propylamino, 2-piperidinoethylamino, 3-piperidinopropylamino,
 4-piperidinobutylamino, piperidin-3-ylamino, piperidin-4-ylamino,
 piperidin-3-ylmethylanino, 2-piperidin-3-ylethylamino, piperidin-4-ylmethylanino,
 2-piperidin-4-ylethylamino, 2-homopiperidin-1-ylethylamino,
 20 3-homopiperidin-1-ylpropylamino, 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino,
 4-piperazin-1-ylbutylamino, 2-homopiperazin-1-ylethylamino or
 3-homopiperazin-1-ylpropylamino,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent
 are optionally separated by the insertion into the chain of a group selected from O, NH,

- 25 N(Me), CH=CH and C≡C,

and when R¹ is a vinyl or ethynyl group, the R¹ substituent optionally bears at the
 terminal CH₂= or HC≡ position a substituent selected from

- N-(2-dimethylaminoethyl)carbamoyl, N-(3-dimethylaminopropyl)carbamoyl,
 methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 4-methylaminobutyl,
 30 dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl and
 4-dimethylaminobutyl, or from a group of the formula :



- 19 -

wherein X^2 is a direct bond or is NHCO or N(Me)CO and Q^2 is imidazolylmethyl, 2-imidazolylethyl, 3-imidazolylpropyl, pyridylmethyl, 2-pyridylethyl, 3-pyridylpropyl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, morpholinomethyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl or 4-piperazin-1-ylbutyl,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro or chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxy, acetamido and N-methylacetamido,

and wherein any phenyl, imidazolyl, triazolyl, pyridyl or heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and methoxy, and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R^1 substituent is optionally N-substituted with allyl, 2-propynyl, methylsulphonyl, acetyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents.

(g) m is 1 and the R^1 group is located at the 6- or 7-position and is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, benzyloxy, 2-imidazol-1-ylethoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy,

- 20 -

pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,
 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-
 4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy,
 5 piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, 2-piperidin-3-ylethoxy,
 piperidin-4-ylmethoxy, 2-piperidin-4-ylethoxy, 2-homopiperidin-1-ylethoxy,
 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,
 2-homopiperazin-1-ylethoxy or 3-homopiperazin-1-ylpropoxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent
 10 are optionally separated by the insertion into the chain of a group selected from O, NH,
 CH=CH and C≡C,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each
 said CH₂ or CH₃ group one or more chloro groups or a substituent selected from hydroxy,
 amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino,
 15 N-ethyl-N-methylamino, N-isopropyl-N-methylamino and acetoxy,

and wherein any phenyl or heterocyclyl group within a substituent on R¹ optionally
 bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro,
 trifluoromethyl, hydroxy, amino, methyl, ethyl and methoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2
 20 oxo substituents;

(h) n is 0;


(i) n is 1 or 2 and the R³ groups, which may be the same or different, are located at the
 3-, 5- and/or 6-positions of the benzofuran-7-yl group and are selected from halogeno,
 trifluoromethyl, cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy;

25 (j) n is 1 or 2 and the R³ groups, which may be the same or different, are located at the
 3-, 5- and/or 6-positions of the benzofuran-7-yl group and are selected from fluoro, chloro,
 bromo, iodo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl,
 1-propynyl, 2-propynyl, methoxy and ethoxy;

(k) n is 1 and the R³ group is located at the 5- or 6-position of the benzofuran-7-yl group,
 30 especially the 6-position, and is selected from chloro, bromo, trifluoromethyl, cyano, hydroxy,
 methyl, ethyl, methoxy and ethoxy;

- 21 -


- (l) m is 1 or 2, and each R¹ group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino and N-(1-6C)alkyl-
 5 (2-6C)alkanoylamino, or from a group of the formula :



- wherein X¹ is selected from O, N(R⁴), CON(R⁴), N(R⁴)CO and OC(R⁴)₂ wherein R⁴ is hydrogen or (1-6C)alkyl, and Q¹ is aryl, aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or X¹ is a direct bond and
 10 Q¹ is aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl,


- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, N(R⁵), CON(R⁵), N(R⁵)CO, CH=CH and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl, or, when the
 15 inserted group is N(R⁵), R⁵ may also be (2-6C)alkanoyl,

- and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno groups or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyloxy, (2-6C)alkanoylamino and N-(1-6C)alkyl-(2-6C)alkanoylamino, or from a
 20 group of the formula :




- wherein X³ is a direct bond or is selected from O, N(R⁶), CON(R⁷), N(R⁷)CO and C(R⁷)₂O, wherein R⁷ is hydrogen or (1-6C)alkyl, and Q³ is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

- 25 and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, N-(1-6C)alkylcarbamoyl, N-di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected
 30 from a group of the formula :



- 22 -


wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the formula :



wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents;

(m) m is 1 or 2, and each R^1 group, which may be the same or different, is selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, dipropylamino, N-methylcarbamoyl, N,N-dimethylcarbamoyl, acetamido, propionamido, acrylamido and propiolamido, or from a group of the formula :



wherein X^1 is selected from O, NH, CONH, NHCO and OCH_2 and Q^1 is phenyl, benzyl, cyclopropylmethyl, 2-thienyl, 1-imidazolyl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 2-, 3- or 4-pyridyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl, 2-(1,2,4-triazolyl)ethyl, 3-(1,2,4-triazolyl)propyl, 2-, 3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3- or 4-pyridyl)propyl, tetrahydrofuran-3-yl, 3- or 4-tetrahydropyranyl, 1-, 2- or 3-pyrrolidinyl, morpholino, 1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl, piperidino, piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl,

- 23 -

- 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl,
 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-(1,2,3,6-tetrahydropyridin-1-yl)ethyl, 3-(1,2,3,6-tetrahydropyridin-1-yl)propyl, 4-(1,2,3,6-tetrahydropyridin-1-yl)butyl,
 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl,
 5 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,
 or wherein X¹ is a direct bond and Q¹ is benzyl, cyclopropylmethyl, 2-imidazol-1-ylethyl, 3-imidazol-1-ylpropyl, 2-(1,2,3-triazolyl)ethyl, 3-(1,2,3-triazolyl)propyl,
 2-(1,2,4-triazolyl)ethyl, 3-(1,2,4-triazolyl)propyl, 2-, 3- or 4-pyridylmethyl, 2-(2-, 3- or 4-pyridyl)ethyl, 3-(2-, 3- or 4-pyridyl)propyl, 1-, 2- or 3-pyrrolidinylmethyl,
 10 morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl,
 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-
 15 4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl,
 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,
 20 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CONH, NHCO, CH=CH and C≡C,
 and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more fluoro or chloro groups or a substituent selected from
 25 hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxy, acetamido and N-methylacetamido or from a group of the formula :


$$-X^3-Q^3$$

 wherein X³ is a direct bond or is selected from O, NH, CONH, NHCO and CH₂O and Q³ is
 30 pyridyl, pyridylmethyl, pyrrolidin-1-yl, pyrrolidin-2-yl, morpholino, piperidino, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-2-ylpropyl, 2-morpholinoethyl,


- 24 -

3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, piperidin-3-ylmethyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 2-piperidin-4-ylethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl,

- and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹
 5 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, allyl, 2-propynyl, methoxy, methylsulphonyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and acetyl, or optionally bears 1 substituent selected from a group of the formula :



- 10 wherein X⁴ is a direct bond or is selected from O and NH and R⁸ is 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, methylaminomethyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-ethylaminoethyl, 3-ethylaminopropyl, dimethylaminomethyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, acetamidomethyl,
 15 methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl or tert-butoxycarbonylaminomethyl, and from a group of the formula :



- wherein X⁵ is a direct bond or is selected from O, NH and CO and Q⁴ is pyrrolidin-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, morpholinomethyl,
 20 2-morpholinoethyl, 3-morpholinopropyl, piperidinomethyl, 2-piperidinoethyl, 3-piperidinopropyl, piperazin-1-ylmethyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

- and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2
 25 oxo substituents;
 (n) m is 1 and the R¹ group is located at the 5-, 6- or 7-position or m is 2 and each R¹ group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R¹ is selected from amino, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido,
 30 propionamido, cyclopentyloxy, cyclohexyloxy, phenoxy, benzyloxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, cyclopropylmethoxy, 2-imidazol-1-ylethoxy, 3-imidazol-1-ylpropoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy,

- 25 -

- 2-(1,2,4-triazol-1-yl)ethoxy, 3-(1,2,4-triazol-1-yl)propoxy, pyrid-2-ylmethoxy, pyrid-3-ylmethoxy, pyrid-4-ylmethoxy,
 2-pyrid-2-ylethoxy, 2-pyrid-3-ylethoxy, 2-pyrid-4-ylethoxy, 3-pyrid-2-ylpropoxy,
 3-pyrid-3-ylpropoxy, 3-pyrid-4-ylpropoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,
 5 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,
 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy,
 piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy,
 10 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy,
 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy,
 2-(1,2,3,6-tetrahydropyridin-1-yl)ethoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy,
 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,
 4-piperazin-1-ylbutoxy, 2-homopiperazin-1-ylethoxy, 3-homopiperazin-1-ylpropoxy,
 15 2-pyrrolidin-1-ylethylamino, 3-pyrrolidin-1-ylpropylamino, 4-pyrrolidin-1-ylbutylamino,
 pyrrolidin-3-ylamino, pyrrolidin-2-ylmethethylamino, 2-pyrrolidin-2-ylethylamino,
 3-pyrrolidin-2-ylpropylamino, 2-morpholinoethylamino, 3-morpholinopropylamino,
 4-morpholinobutylamino, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethylamino,
 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propylamino, 2-piperidinoethylamino,
 20 3-piperidinopropylamino, 4-piperidinobutylamino, piperidin-3-ylamino, piperidin-4-ylamino,
 piperidin-3-ylmethethylamino, 2-piperidin-3-ylethylamino, piperidin-4-ylmethethylamino,
 2-piperidin-4-ylethylamino, 2-homopiperidin-1-ylethylamino,
 3-homopiperidin-1-ylpropylamino, 2-(1,2,3,6-tetrahydropyridin-1-yl)ethylamino,
 3-(1,2,3,6-tetrahydropyridin-1-yl)propylamino, 4-(1,2,3,6-tetrahydropyridin-1-yl)butylamino,
 25 2-piperazin-1-ylethylamino, 3-piperazin-1-ylpropylamino, 4-piperazin-1-ylbutylamino,
 2-homopiperazin-1-ylethylamino or 3-homopiperazin-1-ylpropylamino,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CH=CH and C≡C,

- 30 and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more fluoro or chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diisopropylamino,

- 26 -

N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino, acetoxy, acetamido and N-methylacetamido,

and wherein any phenyl, imidazolyl, triazolyl, pyridyl or heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 substituents, which may be the same or different,
 5 selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl and methoxy, and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R¹ substituent is optionally N-substituted with methyl, ethyl, propyl, allyl, 2-propynyl, methylsulphonyl, acetyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl,
 10 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-fluoroethyl, 3-fluoropropyl, 2-chloroethyl, 3-chloropropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last
 15 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents;

- (o) n is 1 or 2 and the R³ groups, which may be the same or different, are selected from halogeno, trifluoromethyl, cyano, hydroxy, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and
 20 (1-6C)alkoxy;
- (p) n is 1 or 2 and the R³ groups, which may be the same or different, are located at the 3-, 4-, 5- and/or 6-positions of the benzofuran-7-yl group and are selected from fluoro, chloro, bromo, iodo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, isopropenyl, ethynyl, 1-propynyl, 2-propynyl, methoxy and ethoxy; and
- 25 (q) n is 1 and the R³ group is located at the 4-, 5- or 6-position of the benzofuran-7-yl group, especially the 6-position, and is selected from chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, methoxy and ethoxy.

Further compounds for use according to the invention include, for example, quinoline derivatives of the Formula I, or pharmaceutically-acceptable salts thereof, wherein, unless
 30 otherwise stated, each of Z, m, R¹, n and R³ has any of the meanings defined hereinbefore provided that :-

- 27 -

(A) R¹ substituents may only be located at the 5-, 6- and/or 7-positions on the quinoline ring *i.e.* the 2- and 8-positions remain unsubstituted; or

(B) R¹ substituents may only be located at the 6- and/or 7-positions on the quinoline ring *i.e.* the 2-, 5- and 8-positions remain unsubstituted.

5 A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

Z is O or NH;

m is 1 and the R¹ group is located at the 5-, 6- or 7-position or m is 2 and each R¹ group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and
 10 7-positions and R¹ is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, 2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy,
 15 pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy,
 20 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy, 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-(1,2,3,6-tetrahydropyridin-1-yl)ethoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy, 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy, 2-homopiperazin-1-ylethoxy and 3-homopiperazin-1-ylpropoxy,
 25 and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH, N(Me), CH=CH and C≡C,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more chloro groups or a substituent selected from hydroxy,
 30 amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diethylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino and acetoxo;

- 28 -

and wherein any heteroaryl or heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, N-methylcarbamoyl and N,N-dimethylcarbamoyl and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or
 5 homopiperazin-1-yl group within a R¹ substituent is optionally N-substituted with methyl, ethyl, propyl, allyl, prop-2-ynyl, methylsulphonyl, acetyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-fluoroethyl, 3-fluoropropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl,
 10 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents; and

15 n is 0 or 1 and the R³ group, if present, is located at the 3-, 4-, 5- or 6-position of the benzofuran-7-yl group and is selected from fluoro, chloro, bromo, iodo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, ethynyl, methoxy and ethoxy, or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
 20 containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

Z is O or NH;

m is 1 and the R¹ group is located at the 5-, 6- or 7-position or m is 2 and each R¹
 25 group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R¹ is selected from hydroxy, amino, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, pent-4-ynyloxy, hex-5-ynyloxy, methylamino, ethylamino, dimethylamino, diethylamino, acetamido, propionamido, 2-imidazol-1-ylethoxy, 2-(1,2,4-triazol-1-yl)ethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy,
 30 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,

- 29 -

2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, piperidin-3-yloxy, piperidin-4-yloxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 3-piperidin-3-ylpropoxy, 2-piperidin-4-ylethoxy,
 5 3-piperidin-4-ylpropoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy, 2-homopiperazin-1-ylethoxy and 3-homopiperazin-1-ylpropoxy,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, NH,

10 N(Me), CH=CH and C≡C,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more chloro groups or a substituent selected from hydroxy, amino, methoxy, methylsulphonyl, methylamino, dimethylamino, diethylamino, N-ethyl-N-methylamino, N-isopropyl-N-methylamino, N-methyl-N-propylamino and acetoxy;

15 and wherein any heteroaryl or heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, trifluoromethyl, hydroxy, amino, carbamoyl, methyl, ethyl, methoxy, N-methylcarbamoyl and N,N-dimethylcarbamoyl and a pyrrolidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl or homopiperazin-1-yl group within a R¹ substituent is optionally N-substituted with allyl,
 20 methylsulphonyl, acetyl, 2-methoxyethyl, 3-methoxypropyl, cyanomethyl, 2-aminoethyl, 3-aminopropyl, 2-methylaminoethyl, 3-methylaminopropyl, 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-1-ylpropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-piperidinoethyl, 3-piperidinopropyl, 2-piperazin-1-ylethyl or 3-piperazin-1-ylpropyl, the last 8 of which substituents each optionally bears 1 or 2
 25 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy,

and wherein any heterocyclyl group within a substituent on R¹ optionally bears 1 or 2 oxo substituents; and

n is 0 or 1 and the R³ group, if present, is located at the 3-, 5- or 6-position of the
 30 benzofuran-7-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, vinyl, allyl, ethynyl, methoxy and ethoxy, or a pharmaceutically-acceptable acid-addition salt thereof;

- 30 -

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

5 Z is O or NH;

m is 2 and the first R¹ group is located at the 6-position and is selected from hydroxy, methoxy, ethoxy and propoxy, and the second R¹ group is located at the 7-position and is selected from 2-hydroxyethoxy, 3-hydroxypropoxy, 4-hydroxybutoxy, 2-methoxyethoxy, 3-methoxypropoxy, 4-methoxybutoxy, 2-(2-hydroxyethoxy)ethoxy, 10 2-(2-methoxyethoxy)ethoxy, 2-dimethylaminoethoxy, 3-dimethylaminopropoxy, 4-dimethylaminobutoxy, 2-diethylaminoethoxy, 3-diethylaminopropoxy, 4-diethylaminobutoxy, 2-diisopropylaminoethoxy, 3-diisopropylaminopropoxy, 4-diisopropylaminobutoxy, 2-(N-isopropyl-N-methylamino)ethoxy, 3-(N-isopropyl-N-methylamino)propoxy, 4-(N-isopropyl-N-methylamino)butoxy, 15 2-(N-allylamino)ethoxy, 3-(N-allylamino)propoxy, 2-(N-allyl-N-methylamino)ethoxy, 3-(N-allyl-N-methylamino)propoxy, 2-(N-prop-2-ynylamino)ethoxy, 3-(N-prop-2-ynylamino)propoxy, 2-(N-methyl-N-prop-2-ynylamino)ethoxy, 3-(N-methyl-N-prop-2-ynylamino)propoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, 20 N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy, 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, piperidin-3-yloxy, N-methylpiperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, 25 piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 30 3-(4-methylpiperazin-1-yl)propoxy, 4-(4-methylpiperazin-1-yl)butoxy, 2-(4-allylpiperazin-1-yl)ethoxy, 3-(4-allylpiperazin-1-yl)propoxy, 4-(4-allylpiperazin-1-yl)butoxy, 2-(4-methylsulphonylpiperazin-1-yl)ethoxy,

- 31 -

3-(4-methylsulphonylpiperazin-1-yl)propoxy, 4-(4-methylsulphonylpiperazin-1-yl)butoxy,
 2-(4-acetylpiperazin-1-yl)ethoxy, 3-(4-acetylpiperazin-1-yl)propoxy,
 4-(4-acetylpiperazin-1-yl)butoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy,
 3-(4-cyanomethylpiperazin-1-yl)propoxy, 4-(4-cyanomethylpiperazin-1-yl)butoxy,
 5 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy, 2-chloroethoxy, 3-chloropropoxy,
 2-methylsulphonylethoxy and 3-methylsulphonylpropoxy,

and wherein any CH₂ group within the second R¹ group that is attached to two carbon atoms optionally bears a hydroxy group or acetoxy group on said CH₂ group,

and wherein any heterocyclyl group within the second R¹ group optionally bears 1 or 2
 10 substituents selected from fluoro, hydroxy, methyl and oxo; and

n is 0 or n is 1 and the R³ group, if present, is located at the 5- or 6-position of the benzofuran-7-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl, ethyl, ethynyl, methoxy and ethoxy,
 or a pharmaceutically-acceptable acid-addition salt thereof;

15 in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

Z is O or NH;

20 m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from 2-dimethylaminoethoxy, 3-dimethylaminopropoxy, 4-dimethylaminobutoxy, 2-diethylaminoethoxy, 3-diethylaminopropoxy, 4-diethylaminobutoxy, 2-diisopropylaminoethoxy, 3-diisopropylaminopropoxy, 4-diisopropylaminobutoxy, 2-(N-isopropyl-N-methylamino)ethoxy,
 25 3-(N-isopropyl-N-methylamino)propoxy, 4-(N-isopropyl-N-methylamino)butoxy, 2-(N-isobutyl-N-methylamino)ethoxy, 3-(N-isobutyl-N-methylamino)propoxy, 4-(N-isobutyl-N-methylamino)butoxy, 2-(N-allyl-N-methylamino)ethoxy, 3-(N-allyl-N-methylamino)propoxy, 2-(N-prop-2-ynylamino)ethoxy, 3-(N-prop-2-ynylamino)propoxy, 2-(N-methyl-N-prop-2-ynylamino)ethoxy,
 30 3-(N-methyl-N-prop-2-ynylamino)propoxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,

- 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy,
 piperidin-3-yloxy, N-methylpiperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy,
 5 piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy,
N-cyanomethylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy,
N-methylpiperidin-4-ylmethoxy, N-cyanomethylpiperidin-4-ylmethoxy,
 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy,
 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy,
 10 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy,
 3-(N-methylpiperidin-4-yl)propoxy, 2-(4-hydroxypiperidin-1-yl)ethoxy,
 3-(4-hydroxypiperidin-1-yl)propoxy, 4-(4-hydroxypiperidin-1-yl)butoxy,
 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 4-homopiperidin-1-ylbutoxy,
 2-(1,2,3,6-tetrahydropyridin-1-yl)ethoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy,
 15 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy, 2-piperazin-1-ylethoxy,
 2-(4-methylpiperazin-1-yl)ethoxy, 3-piperazin-1-ylpropoxy,
 3-(4-methylpiperazin-1-yl)propoxy, 4-piperazin-1-ylbutoxy,
 4-(4-methylpiperazin-1-yl)butoxy, 2-(4-allylpiperazin-1-yl)ethoxy,
 3-(4-allylpiperazin-1-yl)propoxy, 4-(4-allylpiperazin-1-yl)butoxy,
 20 2-(4-prop-2-ynylpiperazin-1-yl)ethoxy, 3-(4-prop-2-ynylpiperazin-1-yl)propoxy,
 4-(4-prop-2-ynylpiperazin-1-yl)butoxy, 2-(4-methylsulphonylpiperazin-1-yl)ethoxy,
 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 4-(4-methylsulphonylpiperazin-1-yl)butoxy,
 2-(4-acetylpiperazin-1-yl)ethoxy, 3-(4-acetylpiperazin-1-yl)propoxy,
 4-(4-acetylpiperazin-1-yl)butoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy,
 25 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 4-[4-(2-fluoroethyl)piperazin-1-yl]butoxy,
 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy,
 4-(4-cyanomethylpiperazin-1-yl)butoxy, 2-(2-piperazin-1-ylethoxy)ethoxy,
 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy, 2-chloroethoxy, 3-chloropropoxy,
 4-chlorobutoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy,
 30 2-tetrahydropyran-4-ylethoxy, 3-tetrahydropyran-4-ylpropoxy, 2-pyrrol-1-ylethoxy,
 3-pyrrol-1-ylpropoxy, 2-(2-pyridyloxy)ethoxy, 3-(2-pyridyloxy)propoxy,

- 33 -

2-(3-pyridyloxy)ethoxy, 3-(3-pyridyloxy)propoxy, 2-(4-pyridyloxy)ethoxy,
3-(4-pyridyloxy)propoxy, 2-pyridylmethoxy, 3-pyridylmethoxy and 4-pyridylmethoxy,
and wherein any CH₂ group within the second R¹ group that is attached to two carbon
atoms optionally bears a hydroxy group on said CH₂ group,

5 and wherein any heteroaryl group within the second R¹ group optionally bears 1 or 2
substituents selected from chloro, cyano, hydroxy and methyl, and any heterocyclyl group
within the second R¹ group optionally bears 1 or 2 substituents selected from fluoro, hydroxy,
methyl and oxo; and

n is 0 or n is 1 and the R³ group, if present, is located at the 4-, 5- or 6-position of the
10 benzofuran-7-yl group and is selected from fluoro, chloro, bromo, iodo and cyano,
or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I
15 wherein :

Z is O or NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located
at the 7-position and is selected from 2-dimethylaminoethoxy, 3-dimethylaminopropoxy,
4-dimethylaminobutoxy, 2-diethylaminoethoxy, 3-diethylaminopropoxy,
20 4-diethylaminobutoxy, 2-diisopropylaminoethoxy, 3-diisopropylaminopropoxy,
4-diisopropylaminobutoxy, 2-(N-isopropyl-N-methylamino)ethoxy,
3-(N-isopropyl-N-methylamino)propoxy, 4-(N-isopropyl-N-methylamino)butoxy,
2-(N-isobutyl-N-methylamino)ethoxy, 3-(N-isobutyl-N-methylamino)propoxy,
4-(N-isobutyl-N-methylamino)butoxy, 2-(N-allyl-N-methylamino)ethoxy,
25 3-(N-allyl-N-methylamino)propoxy, 2-(N-prop-2-ynylamino)ethoxy,
3-(N-prop-2-ynylamino)propoxy, 2-(N-methyl-N-prop-2-ynylamino)ethoxy,
3-(N-methyl-N-prop-2-ynylamino)propoxy, 2-pyrrolidin-1-ylethoxy,
3-pyrrolidin-1-ylpropoxy, 4-pyrrolidin-1-ylbutoxy, pyrrolidin-3-yloxy,
N-methylpyrrolidin-3-yloxy, pyrrolidin-2-ylmethoxy, 2-pyrrolidin-2-ylethoxy,
30 3-pyrrolidin-2-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy,
2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-
4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy,

- 34 -

- piperidin-3-yloxy, N-methylpiperidin-3-yloxy, piperidin-4-yloxy, N-methylpiperidin-4-yloxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, N-cyanomethylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, N-cyanomethylpiperidin-4-ylmethoxy,
- 5 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 4-homopiperidin-1-ylbutoxy, 2-piperazin-1-ylethoxy,
- 10 2-(4-methylpiperazin-1-yl)ethoxy, 3-piperazin-1-ylpropoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-piperazin-1-ylbutoxy, 4-(4-methylpiperazin-1-yl)butoxy, 2-(4-allylpiperazin-1-yl)ethoxy, 3-(4-allylpiperazin-1-yl)propoxy, 4-(4-allylpiperazin-1-yl)butoxy, 2-(4-methylsulphonylpiperazin-1-yl)ethoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy,
- 15 4-(4-methylsulphonylpiperazin-1-yl)butoxy, 2-(4-acetylpiperazin-1-yl)ethoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 4-(4-acetylpiperazin-1-yl)butoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 4-(4-cyanomethylpiperazin-1-yl)butoxy, 2-(2-piperazin-1-ylethoxy)ethoxy, 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy, 2-chloroethoxy, 3-chloropropoxy,
- 20 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-tetrahydropyran-4-ylethoxy, 3-tetrahydropyran-4-ylpropoxy, 2-pyrrol-1-ylethoxy, 3-pyrrol-1-ylpropoxy, 2-(2-pyridyloxy)ethoxy, 3-(2-pyridyloxy)propoxy, 2-(3-pyridyloxy)ethoxy, 3-(3-pyridyloxy)propoxy, 2-(4-pyridyloxy)ethoxy, 3-(4-pyridyloxy)propoxy, 2-pyridylmethoxy, 3-pyridylmethoxy and 4-pyridylmethoxy,
- 25 and wherein any CH₂ group within the second R¹ group that is attached to two carbon atoms optionally bears a hydroxy group on said CH₂ group,
- and wherein any heteroaryl group within the second R¹ group optionally bears 1 or 2 substituents selected from chloro, cyano, hydroxy and methyl, and any heterocyclyl group within the second R¹ group optionally bears 1 or 2 substituents selected from fluoro, hydroxy,
- 30 methyl and oxo; and
- n is 0 or n is 1 and the R³ group, if present, is located at the 6-position of the benzofuran-7-yl group and is selected from fluoro, chloro and bromo,

- 35 -

or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I

5 wherein :

Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy, 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 3-(N-methylpiperidin-3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 15 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy, 2-(1,2,3,6-tetrahydropyridin-1-yl)ethoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy, 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy, 2-(4-hydroxypiperidin-1-yl)ethoxy, 3-(4-hydroxypiperidin-1-yl)propoxy, 4-(4-hydroxypiperidin-1-yl)butoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 4-piperazin-1-ylbutoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-(4-methylpiperazin-1-yl)butoxy, 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-prop-2-ynylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 4-(4-acetylpiperazin-1-yl)butoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy, 25 3-chloropropoxy, 4-chlorobutoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(2-methoxyethoxy)ethoxy, 2-(4-pyridyloxy)ethoxy, 3-pyridylmethoxy and 2-cyanopyrid-4-ylmethoxy; and

n is 0 or n is 1 and the R³ group, if present, is located at the 4-, 5- or 6-position of the benzofuranyl group and is selected from fluoro, chloro, bromo and iodo,

30 or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

- 36 -

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located
 5 at the 7-position and is selected from 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,
 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-
 4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,
 3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy,
 piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy,
 10 2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 3-(N-methylpiperidin-
 3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy,
 3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy,
 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,
 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-methylsulphonylpiperazin-1-yl)propoxy,
 15 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy,
 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy,
 3-chloropropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy,
 2-(4-pyridyloxy)ethoxy, 3-pyridylmethoxy and 2-cyanopyrid-4-ylmethoxy; and

n is 0 or n is 1 and the R³ group, if present, is located at the 6-position of the
 20 benzofuranyl group and is selected from chloro and bromo;
 or a pharmaceutically-acceptable acid-addition salt thereof.

in the manufacture of a medicament for use as an anti-proliferative agent in the
 containment and/or treatment of solid tumour disease.

The use of a quinoline derivative of the Formula I as claimed in claim 1 wherein :

25 Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located
 at the 7-position and is selected from methoxy, 3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-
 4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 3-(1,2,3,6-
 tetrahydropyridin-1-yl)propoxy, 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy, 3-(4-
 30 hydroxypiperidin-1-yl)propoxy, 3-piperazin-1-ylpropoxy, 3-(4-methylpiperazin-1-yl)propoxy,
 4-(4-methylpiperazin-1-yl)butoxy, 3-(4-prop-2-ynylpiperazin-1-yl)propoxy, 3-(4-

- 37 -

acetylpiperazin-1-yl)propoxy, 4-(4-acetylpiperazin-1-yl)butoxy,
 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, and 2-(2-methoxyethoxy)ethoxy; and
 n is 0 or n is 1 and the R³ group, if present, is located at the 3-, 4-, or 6-position of the
 benzofuranyl group and is selected from chloro, bromo, iodo and methoxy,
 5 or a pharmaceutically-acceptable acid addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
 containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I
 wherein :

10 Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located
 at the 7-position and is selected from methoxy, ethoxy, 2-pyrrolidin-1-ylethoxy,
 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-
 15 4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(1,2,3,6-tetrahydropyridin-
 1-yl)ethoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy, 4-(1,2,3,6-tetrahydropyridin-
 1-yl)butoxy, 2-(4-hydroxypiperidin-1-yl)ethoxy, 3-(4-hydroxypiperidin-1-yl)propoxy,
 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,
 3-(4-methylpiperazin-1-yl)propoxy, 4-(4-methylpiperazin-1-yl)butoxy,
 20 3-(4-allylpiperazin-1-yl)propoxy, 3-(4-prop-2-ynylpiperazin-1-yl)propoxy,
 3-(4-acetylpiperazin-1-yl)propoxy, 4-(4-acetylpiperazin-1-yl)butoxy,
 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-(4-cyanomethylpiperazin-1-yl)ethoxy,
 3-(4-cyanomethylpiperazin-1-yl)propoxy, 3-chloropropoxy, 4-chlorobutoxy,
 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy and 2-(2-methoxyethoxy)ethoxy; and
 25 n is 0 or n is 1 and the R³ group, if present, is located at the 3-, 4-, 5- or 6-position of
 the benzofuranyl group and is selected from fluoro, chloro, bromo, iodo and cyano,
 or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
 containment and/or treatment of solid tumour disease.

30 A further aspect of the invention is the use of a quinoline derivative of the Formula I
 wherein :

Z is NH;

- 38 -

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from methoxy, 3-morpholinopropoxy,

3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy, 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy,

5 3-(4-hydroxypiperidin-1-yl)propoxy, 3-piperazin-1-ylpropoxy,

3-(4-methylpiperazin-1-yl)propoxy, 4-(4-methylpiperazin-1-yl)butoxy,

3-(4-prop-2-ynylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy,

4-(4-acetylpiperazin-1-yl)butoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy,

3-chloropropoxy, 4-chlorobutoxy and 2-(2-methoxyethoxy)ethoxy; and

10 n is 0 or n is 1 and the R³ group, if present, is located at the 3-, 4-, 5- or 6-position of the benzofuranyl group and is selected from fluoro, chloro, bromo, iodo and cyano, or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

15 A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy,

20 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy,

3-piperidinopropoxy, piperidin-3-ylmethoxy, N-methylpiperidin-3-ylmethoxy,

piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-piperidin-3-ylethoxy,

2-(N-methylpiperidin-3-yl)ethoxy, 3-piperidin-3-ylpropoxy, 3-(N-methylpiperidin-

25 3-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy,

3-piperidin-4-ylpropoxy, 3-(N-methylpiperidin-4-yl)propoxy,

2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,

2-(4-cyanomethylpiperazin-1-yl)ethoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy,

2-[2-(4-methylpiperazin-1-yl)ethoxy]ethoxy, 3-chloropropoxy, 2-methylsulphonylethoxy,

30 3-methylsulphonylpropoxy, 2-(4-pyridyloxy)ethoxy, 3-pyridylmethoxy and

2-cyanopyrid-4-ylmethoxy; and

- 39 -

n is 0 or n is 1 and the R³ group, if present, is located at the 6-position of the benzofuran-7-yl group and is selected from chloro and bromo,
or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
5 containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein:

Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located
10 at the 7-position and is selected from 3-(4-methylpiperazin-1-yl)propoxy,

n is 1 and the R³ group is a chloro or bromo group located at the 6-position of the benzofuran-7-yl group,
or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
15 containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

Z is O or NH;

m is 1 and the R¹ group is located at the 5-position and is selected from
20 tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrothien-3-yloxy,
1,1-dioxotetrahydrothien-3-yloxy, tetrahydrothiopyran-4-yloxy,
1,1-dioxotetrahydrothiopyran-4-yloxy, N-methylazetidin-3-yloxy, N-ethylazetidin-3-yloxy,
N-isopropylazetidin-3-yloxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy,
pyrrolidin-2-ylmethoxy, 3-piperidinyloxy, N-methylpiperidin-3-yloxy, 4-piperidinyloxy,
25 N-methylpiperidin-4-yloxy, N-allylpiperidin-4-yloxy, N-prop-2-ynylpiperidin-4-yloxy,
N-acetylpiperidin-4-yloxy, N-methylsulphonylpiperidin-4-yloxy,
N-(2-methoxyethyl)piperidin-4-yloxy, piperidin-3-ylmethoxy,
N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy,
cyclobutyloxy, cyclopentyloxy and cyclohexyloxy,

30 or m is 2 and the first R¹ group is located at the 5-position and is selected from the group of substituents listed immediately above and the second R¹ group is located at the 7-position and is selected from hydroxy, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy,

- 40 -

- 2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy,
 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy,
 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-
 4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidin-4-ylethoxy,
 5 2-(N-methylpiperidin-4-yl)ethoxy, 2-homopiperidin-1-ylethoxy,
 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy,
 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy,
 3-(4-cyanomethylpiperazin-1-yl)propoxy, 2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy,
 2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy,
 10 2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy, 2-tetrahydropyran-4-ylethoxy,
 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy,
 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(2-methoxyethoxy)ethoxy,
 piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-(4-pyridyloxy)ethoxy,
 2-pyridylmethoxy, 3-pyridylmethoxy, 4-pyridylmethoxy and 3-cyanopyrid-4-ylmethoxy;
 15 and wherein any CH₂ group within a R¹ substituent that is attached to two carbon
 atoms optionally bears a hydroxy group on said CH₂ group, and wherein any heterocyclyl
 group within a R¹ substituent optionally bears 1 or 2 oxo substituents,
 and wherein any CH₂ group within a R¹ substituent that is attached to two carbon
 atoms optionally bears a hydroxy group on said CH₂ group;
 20 n is 0 or n is 1 and the R³ group, if present is located at the 3-, 4-, 5- or 6-position of
 the benzofuran-7-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano,
 methyl, ethyl, ethynyl, methoxy and ethoxy,
 or a pharmaceutically-acceptable acid-addition salt thereof;
 in the manufacture of a medicament for use as an anti-proliferative agent in the
 25 containment and/or treatment of solid tumour disease.
- A further aspect of the invention is the use of a quinoline derivative of the Formula I
 wherein :
- m is 2 and the first R¹ group is located at the 5-position and is selected from
 tetrahydrofuran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrothien-3-yloxy,
 30 1,1-dioxotetrahydrothien-3-yloxy, tetrahydrothiopyran-4-yloxy,
 1,1-dioxotetrahydrothiopyran-4-yloxy, N-methylazetidin-3-yloxy, N-ethylazetidin-3-yloxy,
 N-isopropylazetidin-3-yloxy, pyrrolidin-3-yloxy, N-methylpyrrolidin-3-yloxy,

- 41 -

pyrrolidin-2-ylmethoxy, 3-piperidinyloxy, N-methylpiperidin-3-yloxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy, N-allylpiperidin-4-yloxy, N-prop-2-ynylpiperidin-4-yloxy, N-acetylpiperidin-4-yloxy, N-methylsulphonylpiperidin-4-yloxy, N-(2-methoxyethyl)piperidin-4-yloxy, piperidin-3-ylmethoxy,

5 N-methylpiperidin-3-ylmethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy,

and the second R¹ is located at the 7-position and is selected from hydroxy, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-morpholinoethoxy,

10 3-morpholinopropoxy, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethoxy,

3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy,

2-homopiperidin-1-ylethoxy, 3-homopiperidin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy,

15 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy,

2-[(2S)-2-carbamoylpyrrolidin-1-yl]ethoxy, 2-[(2S)-2-(N-methylcarbamoyl)pyrrolidin-1-yl]ethoxy, 2-[(2S)-2-(N,N-dimethylcarbamoyl)pyrrolidin-1-yl]ethoxy,

2-tetrahydropyran-4-ylethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy,

20 2-(2-methoxyethoxy)ethoxy, piperidin-4-ylmethoxy, N-methylpiperidin-4-ylmethoxy, 2-(4-pyridyloxy)ethoxy, 2-pyridylmethoxy, 3-pyridylmethoxy, 4-pyridylmethoxy and 3-cyanopyrid-4-ylmethoxy;

and wherein any CH₂ group within a R¹ substituent that is attached to two carbon atoms optionally bears a hydroxy group on said CH₂ group, and wherein any heterocycl

25 group within a R¹ substituent optionally bears 1 or 2 oxo substituents,

and wherein any CH₂ group within a R¹ substituent that is attached to two carbon atoms optionally bears a hydroxy group on said CH₂ group;

n is 0 or n is 1 and the R³ group, if present is located at the 3-, 5- or 6-position of the benzofuran-7-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano,

30 methyl, ethyl, ethynyl, methoxy and ethoxy,

or a pharmaceutically-acceptable acid-addition salt thereof;

- 42 -

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

- 5 m is 2 and the first R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy, N-methylpyrrolidin-3-yloxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy, piperidin-4-ylmethoxy and N-methylpiperidin-4-ylmethoxy, and the second R¹ is located at the 7-position and is selected from methoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy, 10 3-piperidinopropoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy and 3-methylsulphonylpropoxy; n is 0 or n is 1 and the R³ group, if present, is located at the 6-position of the benzofuran-7-yl group and is selected from chloro and bromo, or a pharmaceutically-acceptable acid-addition salt thereof;

- 15 in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

- 20 m is 2 and the first R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy, 4-piperidinyloxy, N-methylpiperidin-4-yloxy, piperidin-4-ylmethoxy and N-methylpiperidin-4-ylmethoxy, and the second R¹ is located at the 7-position and is selected from methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, benzyloxy, 2-pyrrolidin-1-ylethoxy, 3-pyrrolidin-1-ylpropoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 25 3-(4-hydroxypiperidin-1-yl)propoxy, 2-piperidin-4-ylethoxy, 2-(N-methylpiperidin-4-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-piperazin-1-ylethoxy, 3-piperazin-1-ylpropoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-cyanomethylpiperazin-1-yl)propoxy, 3-methylsulphonylpropoxy, piperidin-4-ylmethoxy and N-methylpiperidin-4-ylmethoxy; 30 n is 0 or n is 1 and the R³ group, if present, is located at the 6-position of the benzofuran-7-yl group and is selected from chloro and bromo, or a pharmaceutically-acceptable acid-addition salt thereof;

- 43 -

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is the use of a quinoline derivative of the Formula I wherein :

5 Z is NH;

 m is 1 and the R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy, 4-piperidinyloxy and N-methylpiperidin-4-yloxy, or m is 2 and the first R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy, 4-piperidinyloxy and N-methylpiperidin-4-yloxy, and the second R¹
 10 group is located at the 7-position and is selected from methoxy, ethoxy, propoxy, 3-pyrrolidin-1-ylpropoxy, 3-piperidinopropoxy, 3-morpholinopropoxy, 3-piperazin-1-ylpropoxy and 3-(4-methylpiperazin-1-yl)propoxy;
 n is 0 or n is 1 and the R³ group, if present, is a chloro group located at the 6-position of the benzofuran-7-yl group,
 15 or a pharmaceutically-acceptable acid-addition salt thereof;

 in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

A further aspect of the invention is a quinoline derivative of the Formula I wherein :

 Z is NH;

20 m is 1 and the R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy and N-methylpiperidin-4-yloxy,
 or m is 2 and the first R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy and N-methylpiperidin-4-yloxy, and the second R¹ group is located at the 7-position and is selected from methoxy and 3-morpholinopropoxy; and
 25 n is 0;

 or a pharmaceutically-acceptable acid-addition salt thereof,

 in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

 A further aspect of the invention is, for example, the use of a quinoline derivative of
 30 the Formula I selected from:-

 4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline,

- 44 -

- 4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-(2-pyrrolidin-1-ylethoxy)-
5-tetrahydropyran-4-yloxyquinoline,
4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-(3-pyrrolidin-1-ylpropoxy)-
5-tetrahydropyran-4-yloxyquinoline,
5 4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-[3-(4-methylpiperazin-1-yl)propoxy]-
5-tetrahydropyran-4-yloxyquinoline,
4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-[2-(4-methylpiperazin-1-yl)ethoxy]-
5-tetrahydropyran-4-yloxyquinoline,
4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-(2-piperidinoethoxy)-5-tetrahydropyran-
10 4-yloxyquinoline and
4-(6-chlorobenzofuran-7-ylamino)-3-cyano-7-(N-methylpiperidin-4-ylmethoxy)-
5-tetrahydropyran-4-yloxyquinoline,
or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
15 containment and/or treatment of solid tumour disease.

A further aspect of the invention is, for example, the use of a quinoline derivative of the Formula I selected from:-

- 4-benzofuran-7-ylamino-3-cyano-5-(N-methylpiperidin-4-yloxy)quinoline,
4-benzofuran-7-ylamino-3-cyano-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline and
20 4-benzofuran-7-ylamino-3-cyano-7-(3-morpholinopropoxy)-5-tetrahydropyran-
4-yloxyquinoline,
or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the
containment and/or treatment of solid tumour disease.


- 25 Particular compounds for use according to the invention include, for example, the
quinoline derivatives of Formula I described hereinafter in Examples 2(3), 2(6)-2(9), 5, 6(2),
6(5), 6(6), 6(8), 8, 9 and 12 or a pharmaceutically-acceptable acid-addition salt thereof.

A quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof,
for use according to the invention may be prepared by any process known to be applicable to
30 the preparation of chemically-related compounds. Such processes are illustrated by the
following representative process variants in which, unless otherwise stated, m, R¹, Z, n and R³
have any of the meanings defined hereinbefore. Necessary starting materials may be obtained


- 45 -

by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative process variants and within the accompanying Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic
 5 chemist.

(a) For the production of those compounds of the Formula I wherein Z is an O, S or N(R²), the reaction of a quinoline of the Formula II



wherein L is a displaceable group and m and R¹ have any of the meanings defined
 10 hereinbefore except that any functional group is protected if necessary, with a compound of the Formula III



wherein Z is O, S, or N(R²) and n, R³ and R² have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that
 15 is present is removed by conventional means.

The reaction may conveniently be carried out in the presence of a suitable acid or in the presence of a suitable base. A suitable acid is, for example, an inorganic acid such as, for example, hydrogen chloride or hydrogen bromide. A suitable base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for
 20 example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal amide, for example sodium hexamethyldisilazane, or, for example, an alkali metal hydride, for example sodium hydride.

25 A suitable displaceable group L is, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, pentafluorophenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group. The reaction is conveniently carried

- 46 -

out in the presence of a suitable inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as

- 5 N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range, for example, 0 to 250°C, preferably in the range 0 to 120°C.

- Typically, the quinoline of the Formula II may be reacted with a compound of the Formula III in the presence of an aprotic solvent such as N,N-dimethylformamide,
10 conveniently in the presence of a base, for example potassium carbonate or sodium hexamethyldisilazane, and at a temperature in the range, for example, 0 to 150°C, preferably in the range, for example, 0 to 70°C.

- The quinoline derivative of the Formula I may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of
15 the formula H-L wherein L has the meaning defined hereinbefore. When it is desired to obtain the free base from the salt, the salt may be treated with a suitable base, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or
20 hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.

- Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question and may be introduced by conventional methods. Protecting groups may be removed
25 by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

- Specific examples of protecting groups are given below for the sake of convenience, in
30 which "lower", as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below

these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned are, of course, within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or arylaliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably
5 containing 1-20 carbon atoms). Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (for example isopropyl, and tert-butyl); lower alkoxy- lower alkyl groups (for example methoxymethyl, ethoxymethyl and isobutoxymethyl); lower acyloxy-lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl); lower
10 alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl); aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (for example trimethylsilyl and tert-butyldimethylsilyl); tri(lower alkyl)silyl-lower alkyl groups (for example trimethylsilylethyl); and (2-6C)alkenyl groups (for example allyl). Methods
15 particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed cleavage.

Examples of hydroxy protecting groups include lower alkyl groups (for example tert-butyl), lower alkenyl groups (for example allyl); lower alkanoyl groups (for example acetyl); lower alkoxycarbonyl groups (for example tert-butoxycarbonyl);
20 lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for example trimethylsilyl and tert-butyldimethylsilyl) and aryl-lower alkyl (for example benzyl) groups.


Examples of amino protecting groups include formyl, aryl-lower alkyl groups (for
25 example benzyl and substituted benzyl, 4-methoxybenzyl, 2-nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-4-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl);
30 trialkylsilyl (for example trimethylsilyl and tert-butyldimethylsilyl); alkylidene (for example methylenidene) and benzylenidene and substituted benzylenidene groups.

- 48 -

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis for groups such as 2-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as 2-nitrobenzyloxycarbonyl.

5 The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents and to Protective Groups in Organic Synthesis, 2nd Edition, by T. Green *et al.*, also published by John Wiley & Son, for general guidance on protecting groups.

Quinoline starting materials of the Formula II may be obtained by conventional
10 procedures such as those disclosed in International Patent Applications WO 98/43960 and WO 00/68201. For example, a 1,4-dihydroquinolin-4-one of Formula IV




IV

wherein m and R¹ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, may be reacted with a halogenating agent such as thionyl
15 chloride, phosphoryl chloride or a mixture of carbon tetrachloride and triphenylphosphine whereafter any protecting group that is present is removed by conventional means.

The 4-chloroquinoline so obtained may be converted, if required, into a
4-pentafluorophenoxyquinoline by reaction with pentafluorophenol in the presence of a
suitable base such as potassium carbonate and in the presence of a suitable solvent such as
20 N,N-dimethylformamide.


7-Aminobenzofuran starting materials (Formula III, for example when Z is NH) may be obtained by conventional procedures as illustrated in the Examples. Corresponding 7-hydroxybenzofuran and 7-mercaptobenzofuran starting materials (Formula III, when Z is O or S respectively) may be obtained by conventional procedures.

25 (b) For the production of those compounds of the Formula I wherein at least one R¹ group is a group of the formula



- 49 -

wherein Q^1 is an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl group or an optionally substituted alkyl group and X^1 is an oxygen atom, the coupling, conveniently in the presence of a suitable dehydrating agent, of a quinoline of the Formula V



V


wherein m , R^1 , Z , n and R^3 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an appropriate alcohol wherein any functional group is protected if necessary whereafter any protecting group that is present is removed by conventional means.

A suitable dehydrating agent is, for example, a carbodiimide reagent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or a mixture of an azo compound such as diethyl or di-tert-butyl azodicarboxylate and a phosphine such as triphenylphosphine. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

(c) For the production of those compounds of the Formula I wherein an R^1 group contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of a quinoline derivative of the Formula VI

- 50 -



VI

wherein L is a displaceable group as defined hereinbefore and Z, n and R³ have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an alcohol or amine as appropriate wherein any protecting group that is present is removed by
 5 conventional means.

The reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near 50°C.

(d) For the production of those compounds of the Formula I wherein R¹ is an
 10 amino-substituted (1-6C)alkoxy group (such as 2-homopiperidin-1-ylethoxy or 3-dimethylaminopropoxy), the reaction of a compound of the Formula I wherein R¹ is a halogeno-substituted (1-6C)alkoxy group with a heterocyclyl compound or an appropriate amine.

The reaction is conveniently carried out in the presence of a suitable inert diluent or
 15 carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near ambient temperature.

(e) For the production of those compounds of the Formula I wherein R¹ is a hydroxy group, the cleavage of a quinoline derivative of the Formula I wherein R¹ is a (1-6C)alkoxy or arylmethoxy group.

20 The cleavage reaction may conveniently be carried out by any of the many procedures known for such a transformation. The cleavage reaction of a compound of the Formula I wherein R¹ is a (1-6C)alkoxy group may be carried out, for example, by treatment of the quinoline derivative with an alkali metal (1-6C)alkylsulphide such as sodium ethanethiolate or, for example, by treatment with an alkali metal diarylphosphide such as lithium
 25 diphenylphosphide. Alternatively the cleavage reaction may conveniently be carried out, for example, by treatment of the quinoline derivative with a boron or aluminium trihalide such as

boron tribromide. The cleavage reaction of a compound of the Formula I wherein R^1 is a arylmethoxy group may be carried out, for example, by hydrogenation of the quinoline derivative in the presence of a suitable metallic catalyst such as palladium or by reaction with an organic or inorganic acid, for example trifluoroacetic acid. Such reactions are preferably
5 carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 10 to 150°C, preferably at or near ambient temperature.

(f) For the production of those compounds of the Formula I wherein an R^1 group contains a primary or secondary amino group, the cleavage of the corresponding compound of the
10 Formula I wherein the R^1 group contains a protected primary or secondary amino group.

Suitable protecting groups for an amino group are, for example, any of the protecting groups disclosed hereinbefore for an amino group. Suitable methods for the cleavage of such amino protecting groups are also disclosed hereinbefore. In particular, a suitable protecting group is a lower alkoxycarbonyl group such as a tert-butoxycarbonyl group which may be
15 cleaved under conventional reaction conditions such as under acid-catalysed hydrolysis, for example in the presence of trifluoroacetic acid.

(g) For the production of those compounds of the Formula I wherein an R^1 group contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation, conveniently in the presence of a suitable base as
20 defined hereinbefore, of a quinoline derivative of the formula I wherein the R^1 group contains a hydroxy group or a primary or secondary amino group as appropriate.

A suitable alkylating agent is, for example, any agent known in the art for the alkylation of hydroxy to alkoxy or substituted alkoxy, or for the alkylation of amino to alkylamino or substituted alkylamino, for example an alkyl or substituted alkyl halide, for
25 example a (1-6C)alkyl chloride, bromide or iodide or a substituted (1-6C)alkyl chloride, bromide or iodide, conveniently in the presence of a suitable base as defined hereinbefore, in a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 10 to 140°C, conveniently at or near ambient temperature.

Conveniently for the production of those compounds of the Formula I wherein R^1
30 contains a (1-6C)alkylamino or substituted (1-6C)alkylamino group, a reductive amination reaction may be employed. For example, for the production of those compounds of the Formula I wherein R^1 contains a N-methyl group, the corresponding compound containing a

- 52 -

N-H group may be reacted with formaldehyde in the presence of a suitable reducing agent. A suitable reducing agent is, for example, a hydride reducing agent, for example an alkali metal aluminium hydride such as lithium aluminium hydride or, preferably, an alkali metal borohydride such as sodium borohydride, sodium cyanoborohydride, sodium triethylborohydride, sodium trimethoxyborohydride and sodium triacetoxymethylborohydride. The reaction is conveniently performed in a suitable inert solvent or diluent, for example tetrahydrofuran and diethyl ether for the more powerful reducing agents such as lithium aluminium hydride, and, for example, methylene chloride or a protic solvent such as methanol and ethanol for the less powerful reducing agents such as sodium triacetoxymethylborohydride and sodium cyanoborohydride. The reaction is performed at a temperature in the range, for example, 10 to 80°C, conveniently at or near ambient temperature.

(h) For the production of those compounds of the Formula I wherein R¹ is an amino-hydroxy-disubstituted (1-6C)alkoxy group (such as 2-hydroxy-3-pyrrolidin-1-ylpropoxy or 3-[N-allyl-N-methylamino]-2-hydroxypropoxy), the reaction of a compound of the Formula I wherein the R¹ group contains an epoxy-substituted (1-6C)alkoxy group with a heterocyclyl compound or an appropriate amine.

The reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near ambient temperature.

(i) For the production of those compounds of the Formula I wherein an R¹ group contains a hydroxy group, the cleavage of the corresponding compound of the Formula I wherein the R¹ group contains a protected hydroxy group.

Suitable protecting groups for a hydroxy group are, for example, any of the protecting groups disclosed hereinbefore. Suitable methods for the cleavage of such hydroxy protecting groups are also disclosed hereinbefore. In particular, a suitable protecting group is a lower alkanoyl group such as an acetyl group which may be cleaved under conventional reaction conditions such as under base-catalysed conditions, for example in the presence of ammonia.

(j) For the production of those compounds of the Formula I wherein Z is a SO or SO₂ group, the oxidation of a compound of Formula I wherein Z is a S group.

Conventional oxidation reagents and reaction conditions for such partial or complete oxidation of a sulphur atom are well known to the organic chemist.

- 53 -

(k) The conversion of a compound of the Formula I wherein an R¹ or R³ substituent is a halogeno group into a further compound of the Formula I wherein the R¹ or R³ substituent is, for example, a cyano, ethynyl or phenyl group.

For example, a compound of the Formula I wherein an R¹ or R³ substituent is a halogeno group may be reacted with a metal cyanide to form a compound of the Formula I wherein an R¹ or R³ substituent is a cyano group. Conveniently, the reaction may be carried out in the presence of a suitable catalyst. A suitable metal cyanide is, for example, a heavy metal cyanide such as zinc cyanide. A suitable catalyst is, for example, an organometallic reagent, for example an organoiron compound such as diphenylphosphinoferrocene. The conversion reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near 100°C.

For example, a compound of the Formula I wherein an R¹ or R³ substituent is a halogeno group may be reacted with a (2-6C)alkyne to form a compound of the Formula I wherein an R¹ or R³ substituent is a (2-6C)alkynyl group such as an ethynyl group. The reaction may conveniently be carried out in the presence of a suitable base as defined hereinbefore and in the presence of a suitable catalyst. For this conversion, a suitable catalyst is, for example, an organometallic reagent, for example an organopalladium compound such as tetrakis(triphenylphosphine)palladium(0). The conversion reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near 60°C.

For example, a compound of the Formula I wherein an R¹ or R³ substituent is a halogeno group may be reacted with an arylboron reagent to form a compound of the Formula I wherein an R¹ or R³ substituent is an aryl group such as a phenyl group. A suitable arylboron reagent is, for example, an arylboronic acid. The reaction may conveniently be carried out in the presence of a suitable catalyst, for example, an organopalladium compound such as tetrakis(triphenylphosphine)palladium(0). The conversion reaction is conveniently carried out in the presence of a suitable inert diluent or carrier as defined hereinbefore and at a temperature in the range 10 to 150°C, preferably at or near 80°C.

When a pharmaceutically-acceptable salt of a quinoline derivative of the Formula I is required for use according to the invention, for example an acid-addition salt, it may be

- 54 -

obtained by, for example, reaction of said quinoline derivative with a suitable acid using a conventional procedure.

Biological Assays

The following assays can be used to measure the effects of the compounds as
5 inhibitors of the MAPK pathway.

Assay to detect MEK inhibition

To evaluate inhibitors of the MAPK pathway a coupled assay was carried out which measures phosphorylation of serine/threonine residues present in the substrate in the presence or absence of inhibitor. Recombinant glutathione S-transferase fusion protein containing
10 human p45MEK1 (GST-MEK) was activated by c-raf (Sf9 insect cell lysate from triple baculoviral infection with c-raf/ras/lck) and used for the assay. Active GST-MEK was first used to activate a recombinant glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) in the presence of ATP and Mg^{2+} for 60min at room temperature in the presence or absence of potential inhibitors. The activated GST-MAPK was then incubated
15 with myelin basic protein (MBP) as substrate for 10min at room temperature in the presence of ATP, Mg^{2+} and ^{33}P -ATP. The reaction was stopped by addition of 20% v/v phosphoric acid. Incorporation of ^{33}P into the myelin basic protein was determined by capture of the substrate on a filter mat, washing and counting using scintillation methods. The extent of inhibition was determined by comparison with untreated controls.

20 The final assay solution contained 10mM Tris, pH 7.5, 0.05mM EGTA, 8.33 μ M [γ ^{33}P]ATP, 8.33mM Mg(OAc)₂, 0.5mM sodium orthovanadate, 0.05%w/v BSA, 6.5ng GST-MEK, 1 μ g GST-MAPK and 16.5 μ g MBP in a reaction volume of 60 μ l.

Compounds tested had IC₅₀ results typically less than 0.5 μ M.

In vitro MAP kinase assay

25 To determine whether compounds were inhibiting GST-MEK or GST-MAPK, a direct assay of MAPK activity was employed. GST-MAPK was activated by a constitutively active GST-MEK fusion protein containing two point mutations (S217E, S221E) and used for the assay in the presence and absence of potential inhibitors. The activated GST-MAPK was incubated with substrate (MBP) for 60min at room temperature in the presence of ATP, Mg^{2+}
30 and ^{33}P -ATP. The reaction was stopped by addition of 20% v/v phosphoric acid. Incorporation of ^{33}P into the myelin basic protein was determined by capture of the substrate on a filter mat, washing and counting using scintillation methods.

- 55 -

The final assay solution contained 12mM Tris, pH 7.5, 0.06mM EGTA, 30 μ M [γ ³³P]ATP, 10mM Mg(OAc)₂, 0.6mM sodium orthovanadate, 0.06%w/v BSA, 28ng GST-MAPK and 16.5 μ g MBP in a reaction volume of 60 μ l.

Compounds of Formula I showed activity in this screen.

5 Cell proliferation assays

Cells were seeded into multi-well plates at 20 000 - 40 000 cells/ml in growth medium containing 5% FCS and incubated overnight at 37°C. The compounds were prepared in fresh medium at an appropriate concentration and added to the wells containing the cells. These were then incubated for a further 72 hours. Cells were then either removed from the wells by
10 incubating with trypsin/EDTA and counted using a Coulter counter, or treated with XTT/PMS in PBSA and optical densities read at 450nm. Compounds of Formula I had IC₅₀ results typically less than 30 μ M.

A pharmaceutical composition for the use of compounds of Formula I according to the invention comprises a quinoline derivative of the Formula I, or a pharmaceutically-acceptable
15 salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The compositions may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or
20 aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

25 The compositions may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

The amount of active ingredient that is combined with one or more excipients to
30 produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active

- 56 -

agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral administration is however preferred, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.

The anti-proliferative treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinoline derivative of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents :-

- (i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea; antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), antiandrogens (for example bicalutamide, flutamide,

- 57 -

nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;

- 5 (iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erb2 antibody trastuzumab [HerceptinTM] and the anti-erb1 antibody cetuximab [C225]), farnesyl
- 10 transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-
- 15 4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
- (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody
- 20 bevacizumab [AvastinTM], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin);
- (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in
- 25 International Patent Applications WO 99/02166, WO00/40529, WO 00/41669, WO01/92224, WO02/04434 and WO02/08213;
- (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
- (viii) gene therapy approaches, including for example approaches to replace aberrant genes
- 30 such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial

- 58 -

nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

- (ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of the Formula I within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.

According to this aspect of the invention there is provided the use of a pharmaceutical product comprising a quinoline derivative of the Formula I as defined hereinbefore and an additional anti-tumour agent as defined hereinbefore for use in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

Although the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of MEK enzyme. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.

The invention will now be illustrated in the following Examples in which, generally :

- (i) operations were carried out at ambient temperature, *i.e.* in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated;
- (ii) evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids by filtration;
- (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany or high pressure liquid chromatography (HPLC) was performed on C18 reverse phase silica, for example on a Dynamax C-18 60Å preparative reversed-phase column;

- 59 -

(iv) yields, where present, are not necessarily the maximum attainable;

(v) in general, the end-products of the Formula I have satisfactory microanalyses and their structures were confirmed by nuclear magnetic resonance (NMR) and/or mass spectral techniques; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform
5 spectrometer and, where appropriate, either positive ion data or negative ion data were collected; NMR chemical shift values were measured on the delta scale [proton magnetic resonance spectra were determined using a Jeol JNM EX 400 spectrometer operating at a field strength of 400MHz, Varian Gemini 2000 spectrometer operating at a field strength of 300MHz or a Bruker AM300 spectrometer operating at a field strength of 300MHz]; the
10 following abbreviations have been used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad;

(vi) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, HPLC, infra-red (IR) and/or NMR analysis;

(vii) melting points are uncorrected and were determined using a Mettler SP62
15 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the Formula I were determined after crystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture;

(viii) where certain compounds were obtained as an acid-addition salt, for example a mono hydrochloride salt or a dihydrochloride salt, the stoichiometry of the salt was based on
20 the number and nature of the basic groups in the compound, the exact stoichiometry of the salt was generally not determined, for example by means of elemental analysis data;

(ix) the following abbreviations have been used:-

DMF	<u>N,N</u> -dimethylformamide
DMSO	dimethylsulphoxide
THF	tetrahydrofuran
DMA	<u>N,N</u> -dimethylacetamide

The compounds of the Examples showed activity in the assays described above.

Example 1**4-benzofuran-7-ylamino-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline dihydrochloride salt**

Sodium hexamethyldisilazane (1M solution in THF; 1.2 ml) was added to a solution of
5 7-aminobenzofuran (0.16 g) in DMF (10 ml) that had been cooled to 0°C and the mixture was
stirred for 5 minutes. A solution of 4-chloro-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-
1-yl)propoxy]quinoline (0.225 g) in DMF (2 ml) was added and the resultant mixture was
stirred at ambient temperature for 24 hours. The reaction mixture was evaporated and the
residue was partitioned between ethyl acetate and water. The organic phase was washed with
10 water and with brine, dried over magnesium sulphate and evaporated. The residue was
purified by column chromatography on silica using increasingly polar mixtures of methylene
chloride and a saturated methanolic ammonia solution as eluent. The material so obtained
was dissolved in diethyl ether and a solution of hydrogen chloride in diethyl ether (1M, 2 ml)
was added. The resultant solid was washed with diethyl ether and dried. There was thus
15 obtained the title compound (0.27 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 2.33 (m,
2H), 2.85 (s, 3H), 3.24–3.89 (m, 10H), 4.0 (s, 3H), 4.33 (m, 2H), 6.84 (s, 1H), 7.34 (d, 1H),
7.42 (t, 1H), 7.51 (s, 1H), 7.69 (d, 1H), 8.01 (s, 1H), 8.24 (s, 1H), 8.91 (s, 1H); Mass
Spectrum : M+H⁺ 472.

The 7-aminobenzofuran used as a starting material was prepared as follows :-

20 Hydrazine hydrate (0.45 ml) was added dropwise to a stirred mixture of
7-nitrobenzofuran (J. Med. Chem., 1988, 31, 1934; 0.5 g), Raney nickel (0.02 g) and methanol
(9 ml) that had been warmed to 55°C. The resultant mixture was heated to reflux for
30 minutes. The catalyst was removed by filtration and the filtrate was evaporated. The
residue was partitioned between methylene chloride and water. The organic phase was dried
25 over magnesium sulphate and evaporated to give 7-aminobenzofuran (0.4 g) as an oil; NMR
Spectrum: (DMSO_d₆) 5.25 (br s, 2H), 6.55 (d, 1H), 6.8 (m, 2H), 6.9 (t, 1H), 7.85 (d, 1H).

The 4-chloro-3-cyano-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline
used as a starting material was prepared as follows :-

A mixture of 3-bromopropanol (20 ml), N-methylpiperazine (29 ml), potassium
30 carbonate (83 g) and ethanol (200 ml) was stirred and heated to reflux for 20 hours. The
mixture was cooled to ambient temperature and filtered. The filtrate was evaporated and the
residue was triturated under diethyl ether. The resultant mixture was filtered and the filtrate

- 61 -


was evaporated. The residue was purified by distillation at about 60-70°C under about 0.2 mm Hg to give 1-(3-hydroxypropyl)-4-methylpiperazine (17 g); NMR Spectrum: (CDCl₃) 1.72 (m, 2H), 2.3 (s, 3H), 2.2-2.8 (m, 8H), 2.6 (t, 2H), 3.8 (t, 2H), 5.3 (br s, 1H).

Diethyl azodicarboxylate (0.25 g) was added dropwise to a suspension of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline (0.2 g; prepared as described in International Patent Application WO 00/68201, disclosed as compound (7) within Preparation 1 therein), 1-(3-hydroxypropyl)-4-methylpiperazine (0.202 g), triphenylphosphine (0.447 g) and methylene chloride (5 ml) and the mixture was stirred at ambient temperature for 2 hours. The resultant mixture was evaporated and the residue was purified by column chromatography on silica using initially increasingly polar mixtures of methylene chloride and ethyl acetate followed by increasingly polar mixtures of methylene chloride, ethyl acetate and a saturated methanolic ammonia solution as eluent. The material so obtained was triturated under diethyl ether. The resultant solid was isolated and dried under vacuum to give the required starting material (0.15 g); NMR Spectrum: (DMSO-d₆ and CF₃CO₂D) 1.95-2.05 (m, 2H), 2.2 (s, 3H), 2.25-2.5 (m, 10H), 4.05 (s, 3H), 4.3 (m, 2H), 7.45 (s, 1H), 7.58 (s, 1H), 9.0 (s, 1H); Mass Spectrum: M+H⁺ 375 and 377.

Example 2

Using an analogous procedure to that described in Example 1, the appropriate 4-chloro-3-cyanoquinoline was reacted with the appropriate 7-aminobenzofuran to give the compounds described in Table I. Unless otherwise stated, each product was obtained as a dihydrochloride salt.

Table I



- 62 -

Compound No. & Note	R ¹	R ²
[1]	3-(4-methylpiperazin-1-yl)propoxy	6-chloro
[2]	3-(4-methylpiperazin-1-yl)propoxy	3-chloro
[3]	3-morpholinopropoxy	hydrogen
[4]	methoxy	5-fluoro
[5]	3-chloropropoxy	4-methoxy
[6]	methoxy	4-methoxy
[7]	3-morpholinopropoxy	4-methoxy
[8]	3-(4-methylpiperazin-1-yl)propoxy	4-methoxy
[9]	methoxy	4-iodo

Notes

[1] The product gave the following characterising data; NMR Spectrum: (DMSO-d₆ and CF₃CO₂D) 2.35 (m, 2H), 2.86 (s, 3H), 3.31–3.9 (m, 10H), 4.01 (s, 3H), 4.36 (m, 2H), 7.10 (d, 1H), 7.51 (d, 1H), 7.53 (s, 1H), 7.79 (d, 1H), 8.03 (d, 1H), 8.27 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 506 and 508.

The 7-amino-6-chlorobenzofuran used as a starting material was prepared as follows :-

Sodium hydride (60% dispersion in mineral oil; 4.6 g) was added to a stirred solution of 6-chloroanthranilic acid (18 g) in DMF (100 ml) and the mixture was stirred at ambient temperature for 30 minutes. Ethyl iodide (10 ml) was added and the reaction mixture was stirred at ambient temperature for 2 days. The solvent was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 4:1 mixture of petroleum ether (b.p. 60-80°C) and ethyl acetate as eluent. There was thus obtained ethyl 6-chloroanthranilate (15.8 g) as an oil; NMR Spectrum: (DMSO-d₆) 1.3 (t, 3H), 4.3 (q, 2H), 5.7 (br s, 2H), 6.6 (d, 1H), 6.7 (d, 1H), 7.1 (t, 1H).

A solution of sodium nitrite (4.5 g) in water (100 ml) was added dropwise during 5 minutes to a stirred suspension of ethyl 6-chloroanthranilate (12.7 g) in a mixture of concentrated sulphuric acid (27.9 ml), water (38 ml) and ice (76 g). The reaction mixture was stirred at 0°C for an additional 20 minutes and then heated to 120°C for 1 hour. The resultant

- 63 -

mixture was poured into a mixture of ice and water and the product was extracted with diethyl ether. The organic phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 4:1 mixture of petroleum ether (b.p. 60-80°C) and methylene chloride as eluent. There was
5 thus obtained ethyl 6-chloro-2-hydroxybenzoate (9.8 g); NMR Spectrum: (DMSO-d₆) 1.3 (t, 3H), 4.3 (q, 2H), 6.9 (d, 1H), 6.95 (d, 1H), 7.25 (d, 1H), 10.45 (br s, 1H).

Allyl bromide (5.5 ml) was added to a stirred mixture of ethyl 6-chloro-2-hydroxybenzoate (9.8 g), 1,5,7-triazabicyclo[4,4,0]dec-5-ene (10.4 g) and acetonitrile (250 ml) and the reaction mixture was stirred at ambient temperature for 20 hours. The
10 mixture was evaporated and the residue was purified by column chromatography on silica using a 17:3 mixture of petroleum ether (b.p. 60-80°C) and diethyl ether as eluent. There was thus obtained ethyl 2-allyloxy-6-chlorobenzoate (10.3 g); NMR Spectrum: (DMSO-d₆) 1.3 (t, 3H), 4.35 (q, 2H), 4.65 (d, 2H), 5.25 (d, 1H), 5.4 (d, 1H), 6.0 (m, 1H), 7.15 (m, 2H), 7.45 (t, 1H).

15 The material so obtained was heated to 230°C for 1 hour. The reaction product was cooled to ambient temperature and purified by column chromatography on silica using a 4:1 mixture of petroleum ether (b.p. 60-80°C) and methylene chloride as eluent. There was thus obtained ethyl 3-allyl-6-chloro-2-hydroxybenzoate (7.3 g); NMR Spectrum: (DMSO-d₆) 1.3 (t, 3H), 3.3 (m, 2H), 4.35 (q, 2H), 5.05 (m, 2H), 5.95 (m, 1H), 6.95 (d, 1H), 7.15 (d, 1H), 9.7 (br
20 s, 1H).

The material so obtained was dissolved in methanol (62 ml) and cooled to -70°C. Ozone was bubbled through the solution for 30 minutes. Dimethyl sulfide (13 ml) was added and the reaction mixture was allowed to warm to ambient temperature. The mixture was evaporated and the residue was partitioned between diethyl ether and water. The organic
25 phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. There was thus obtained 2-(4-chloro-3-ethoxycarbonyl-2-hydroxyphenyl)acetaldehyde which was immediately suspended in 85% phosphoric acid (18 ml) and the mixture was heated to 100°C for 1 hour. The mixture was cooled to ambient temperature and partitioned between diethyl ether and water. The organic phase was washed
30 in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 7:3 mixture of petroleum ether (b.p. 60-80°C) and methylene chloride as eluent. There was thus obtained ethyl

- 64 -

6-chlorobenzofuran-7-carboxylate (5.9 g); NMR Spectrum: (DMSO_d₆) 1.35 (t, 3H), 4.45 (q, 2H), 7.10 (d, 1H), 7.45 (d, 1H), 7.85 (d, 1H), 8.15 (d, 1H).

A mixture of the material so obtained, 35% aqueous potassium hydroxide solution (12.7 ml) and methanol (20 ml) was stirred and heated to reflux for 1 hour. The methanol was
5 evaporated and the residue was diluted with water and acidified to pH1 by the addition of 6N aqueous hydrochloric acid. The resultant precipitate was isolated, washed with water and dried under vacuum over phosphorus pentoxide to give 6-chlorobenzofuran-7-carboxylic acid (4.6 g); NMR Spectrum: (DMSO_d₆) 7.05 (d, 1H), 7.4 (d, 1H), 7.75 (d, 1H), 8.1 (d, 1H).

A mixture of a portion (1 g) of the material so obtained, diphenylphosphoryl azide
10 (2.2 ml), triethylamine (1.4 ml) and tert-butanol (2.7 ml) was stirred and heated to reflux for 18 hours. The mixture was allowed to cool to ambient temperature, poured into water and extracted with ethyl acetate. The organic phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on alumina using increasingly polar solvent mixtures starting with mixtures
15 of petroleum ether and methylene chloride and ending with a 4:1 mixture of methylene chloride and ethyl acetate. There was thus obtained a mixture of 7-amino-6-chlorobenzofuran and tert-butyl 6-chlorobenzofuran-7-carbamate. A solution of the mixture so obtained in methylene chloride (15 ml) was cooled to 0°C and trifluoroacetic acid (1.2 ml) was added. The resultant mixture was stirred for 1 hour. The mixture was evaporated and the residue was
20 partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 3:1 mixture of petroleum ether (b.p. 60-80°C) and methylene chloride as eluent. There was thus obtained 7-amino-6-chlorobenzofuran (0.376 g); NMR Spectrum: (DMSO_d₆) 5.5 (br s, 2H), 6.85 (m, 2H), 7.1 (d, 1H), 7.95 (d, 1H);
25 Mass Spectrum: M+H⁺ 167.

[2] The product gave the following characterising data; NMR Spectrum: (DMSO_d₆ and CF₃CO₂D) 2.27 (m, 2H), 2.82 (s, 3H), 3.11–3.79 (m, 10H), 3.99 (s, 3H), 4.3 (m, 2H), 7.41–7.54 (m, 3H), 7.62 (d, 1H), 8.09 (s, 1H), 8.28 (s, 1H), 8.74 (s, 1H); Mass Spectrum: M+H⁺ 506 and 508.

30 The 7-amino-3-chlorobenzofuran used as a starting material was prepared as follows :-
7-Nitrobenzofuran (1.2 g) was dissolved in glacial acetic acid (12 ml) and chlorine gas was bubbled through the solution for 30 minutes whilst the temperature of the reaction

- 65 -

mixture was maintained at about 18°C. The reaction mixture was evaporated and the residue was purified by column chromatography using a 1:1 mixture of petroleum ether (b.p. 60-80°C) and ethyl acetate as eluent. There was thus obtained a mixture of the *cis*- and *trans*- isomers of 2,3-dichloro-7-nitro-2,3-dihydrobenzofuran (0.77 g); Mass Spectrum:

5 M+H⁺ 233.

After repetition of the preceding reaction, *cis*- and *trans*- 2,3-dichloro-7-nitro-2,3-dihydrobenzofuran (0.85 g) was dissolved in ethanol (35 ml) and a 0.8N aqueous potassium hydroxide solution (45.5 ml) was added. The reaction mixture was stirred at ambient temperature for 1.25 hours. The mixture was concentrated by evaporation, water was
10 added and the mixture was acidified to pH2 by the addition of 6N aqueous hydrochloric acid. The mixture was extracted with diethyl ether. The organic phase was washed with water and with brine, dried over magnesium sulphate and evaporated. There was thus obtained 3-chloro-7-nitrobenzofuran (0.7 g) as a colorless solid; NMR Spectrum: (DMSOd₆) 7.65 (t, 1H), 8.15 (d, 1H), 8.3 (d, 1H), 8.65 (s, 1H).

15 The material so obtained was dissolved in methanol (25 ml) and the solution was added dropwise during 5 minutes to a stirred mixture of hydrazine hydrate (0.81 ml), Raney nickel (0.16 g) and methanol (30 ml) which had been heated to 60°C. The resultant reaction mixture was then heated to reflux for 5 minutes. The reaction mixture was cooled to ambient temperature and the catalyst was removed by filtration. The filtrate was evaporated and the
20 residue was partitioned between methylene chloride and water. The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 1:1 mixture of petroleum ether (b.p. 60-80°C) and ethyl acetate as eluent. There was thus obtained 7-amino-3-chlorobenzofuran (0.41 g); NMR Spectrum: (DMSOd₆) 5.5 (br s, 2H), 6.65 (d, 1H), 6.75 (d, 1H), 7.05 (t, 1H), 8.2 (s, 1H).

25 [3] 4-Chloro-3-cyano-6-methoxy-7-(3-morpholinopropoxy)quinoline (International Patent Application WO 00/68201, page 52) was used as a starting material. The reaction mixture was evaporated and the residue was partitioned between methylene chloride and water. The organic phase was washed with water and with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly
30 polar mixtures of methylene chloride and methanol as eluent. There was thus obtained the required product as a free base. The product gave the following characterising data; NMR Spectrum: (DMSOd₆) 1.96 (m, 2H), 2.33-2.39 (m, 4H), 2.41-2.5 (m, 2H), 3.55-3.6 (m, 4H),

- 66 -

3.92 (s, 3H), 4.21 (t, 2H), 7.01 (d, 1H), 7.24–7.29 (m, 2H), 7.33 (s, 1H), 7.57 (m, 1H), 7.85 (s, 1H), 7.92 (d, 1H), 8.37 (s, 1H), 9.71 (s, 1H); Mass Spectrum: $M+H^+$ 459.

[4] 4-Chloro-3-cyano-6,7-dimethoxyquinoline (International Patent Application

WO 98/43960) was used as a starting material. The reaction mixture was evaporated and the

5 residue was triturated under methylene chloride. The solid so obtained was washed with methylene chloride and diethyl ether and dried. There was thus obtained the required product as a free base. The product gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.74 (s, 3H), 3.81 (s, 3H), 6.39 (m, 1H), 6.64 (m, 1H), 6.74 (d, 1H), 6.89 (s, 1H), 7.7–7.75 (m, 3H); Mass Spectrum: $M-H$ 362.

10 The 7-amino-5-fluorobenzofuran used as a starting material was prepared as follows :-

Allyl bromide (6 ml) was added to a stirred mixture of 4-fluoro-2-nitrophenol (10 g), 1,5,7-triazabicyclo[4,4,0]dec-5-ene (11.5 g) and DMF (120 ml) and the reaction mixture was stirred at ambient temperature for 20 hours. The reaction mixture was then heated to 50°C for 1.5 hours. The mixture was evaporated and the residue was partitioned between diethyl ether 15 and water. The organic phase was washed in turn with a 1N aqueous hydrochloric acid solution, water and brine, dried over magnesium sulphate and evaporated. There was thus obtained 4-allyloxy-3-nitro-1-fluorobenzene (9.6 g); NMR Spectrum: (DMSO_d₆) 4.85 (d, 2H), 5.3 (d, 1H), 5.45 (d, 1H), 6.05 (m, 1H), 7.4 (m, 1H), 7.6 (m, 1H), 7.9 (m, 1H).

A mixture of 4-allyloxy-3-nitro-1-fluorobenzene (8 g) and 1,2-dichlorobenzene 20 (14 ml) was heated to 230°C for 32 minutes in a microwave oven (651W for 3 minutes to raise the temperature to 230°C and then 300W for 29 min). The solvent was evaporated and the residue was mixed with methylene chloride (30 ml) and filtered. The filtrate was evaporated and the residue was purified by column chromatography on silica using a 4:1 mixture of petroleum ether (b.p. 60–80°C) and methylene chloride as eluent. There was thus 25 obtained 2-allyl-4-fluoro-6-nitrophenol (3.5 g) as an oil; NMR Spectrum: (DMSO_d₆) 3.45 (d, 2H), 5.1 (d, 2H), 6.0 (m, 1H), 7.5 (m, 1H), 7.75 (m, 1H), 10.4 (br s, 1H).

The material so obtained was dissolved in methanol and cooled to -78°C. Ozone was bubbled through the solution for 30 minutes. Dimethyl sulfide (5.4 ml) was added and the reaction mixture was allowed to warm to ambient temperature. The mixture was evaporated 30 and the residue was partitioned between diethyl ether and water. The organic phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 1:1 mixture of petroleum

- 67 -

ether (b.p. 60-80°C) and methylene chloride and then a 9:1 mixture of methylene chloride and diethyl ether as eluent. There was thus obtained 2-(5-fluoro-2-hydroxy-3-nitrophenyl)acetaldehyde which was immediately suspended in 85% phosphoric acid (18 ml) and the mixture was heated to 100°C for 1 hour. The mixture was cooled to ambient temperature and partitioned between diethyl ether and water. The organic phase was washed in turn with water and brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using a 1:1 mixture of petroleum ether (b.p. 60-80°C) and methylene chloride as eluent. There was thus obtained 5-fluoro-7-nitrobenzofuran (1.3 g); NMR Spectrum: (DMSO_d₆) 7.2 (d, 1H), 8.05 (m, 2H), 8.35 (d, 1H).

Hydrazine hydrate (0.522 ml) was added dropwise to a stirred mixture of 5-fluoro-7-nitrobenzofuran (0.65 g), Raney nickel (0.03 g) and methanol (12 ml) that had been warmed to 55-60°C. The reaction mixture was then heated to reflux for 45 minutes. The catalyst was removed by filtration and the filtrate was evaporated. The residue was partitioned between methylene chloride and water. The organic phase was dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of petroleum ether (b.p. 60-80°C) and methylene chloride as eluent. There was thus obtained 7-amino-5-fluorobenzofuran (0.206 g); NMR Spectrum: (DMSO_d₆) 5.65 (br s, 2H), 6.3 (m, 1H), 6.55 (m, 1H), 6.8 (d, 1H), 7.9 (d, 1H).

[5] 7-Amino-4-methoxybenzofuran (*J. Med. Chem.*, 1995, 38, 1942-1954) was used as the appropriate 7-aminobenzofuran. The reaction product was purified by column chromatography on silica using increasingly polar mixtures of isohexane and ethyl acetate as eluent. There was thus obtained the required product as a free base which contained some of the corresponding 7-(3-bromopropoxy)quinoline. The material so obtained gave the following characterising data; Mass Spectrum: M+H⁺ 438 and 440.

The 4-chloro-7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline used as a starting material was prepared as follows :-

A mixture of 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline (0.2 g, prepared as described in International Patent Application WO 00/68201, disclosed as compound (7) within Preparation 1 therein), potassium *tert*-butoxide (0.1 g) and DMF (8 ml) was stirred at ambient temperature for 15 minutes. 1-Bromo-3-chloropropane (0.134 g) was added and the reaction mixture was stirred at ambient temperature for 16 hours. The resultant mixture was evaporated and the residue was partitioned between methylene chloride and an aqueous

- 68 -

sodium bicarbonate solution. The organic layer was dried using magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of ethyl acetate and hexane. There was thus obtained 4-chloro-

7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline (0.131 g containing some 4-chloro-

5 7-(3-bromopropoxy)-3-cyano-6-methoxyquinoline); NMR Spectrum: (DMSO_d₆) 2.3 (m, 2H), 3.8 (m, 2H), 4.0 (s, 3H), 4.35 (m, 2H), 7.42 (s, 1H), 7.68 (s, 1H), 8.95 (s, 1H); Mass Spectrum: M+H⁺ 311.

[6] The reaction mixture was stirred at 0°C for 90 minutes and then poured into a dilute aqueous ammonium chloride solution. The precipitate was isolated and dried. There was thus
10 obtained the required product as a free base which gave the following characterising data; NMR Spectrum: (DMSO_d₆) 3.93 (s, 3H), 3.95 (s, 6H), 6.84 (d, 1H), 6.99 (d, 1H), 7.27 (d, 1H), 7.31 (s, 1H), 7.87 (d, 1H), 7.89 (s, 1H), 8.3 (s, 1H), 9.58 (s, 1H); Mass Spectrum: M+H⁺ 376.

[7] The reaction mixture was stirred at 0°C for 90 minutes and then poured into a dilute
15 aqueous ammonium chloride solution. The precipitate was isolated and purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained the required product as a free base which gave the following characterising data; NMR Spectrum: (CDCl₃) 2.09 (m, 2H), 2.45 (m, 4H), 2.54 (t, 2H), 3.54 (s, 3H), 3.71 (m, 4H), 3.95 (s, 3H), 4.24 (t, 2H), 6.64 (d, 1H), 6.89 (s, 1H); 6.91
20 (d, 1H), 6.94 (s, 1H), 7.1 (d, 1H), 7.35 (s, 1H), 7.48 (d, 1H), 8.56 (s, 1H); Mass Spectrum: M+H⁺ 489.

[8] The reaction mixture was stirred at 0°C for 90 minutes and then poured into a dilute aqueous ammonium chloride solution. The precipitate was isolated and dried. There was thus obtained the required product as a free base which gave the following characterising data;
25 NMR Spectrum: (DMSO_d₆) 1.94 (m, 2H), 2.16 (s, 3H), 2.25-2.5 (m, 8H), 2.45 (t, 2H), 3.92 (s, 3H), 3.93 (s, 3H), 4.18 (t, 2H), 6.83 (d, 1H), 6.98 (d, 1H), 7.26 (d, 1H), 7.29 (s, 1H), 7.85 (m, 2H), 8.3 (s, 1H), 9.58 (s, 1H); Mass Spectrum: M+H⁺ 502.

[9] The reaction mixture was stirred at ambient temperature for 1 hour and then poured into a saturated aqueous ammonium chloride solution. The mixture was extracted with
30 methylene chloride and the organic phase was washed with water and with brine, dried over magnesium sulphate and evaporated. The residue was triturated under diethyl ether and the resultant solid was isolated and dried. There was thus obtained the required compound as a

- 69 -

free base containing 1 equivalent of DMF. The material so obtained gave the following characterising data; NMR Spectrum: (CDCl₃) 3.62 (s, 3H), 4.04 (s, 3H), 6.72 (d, 1H), 6.75 (d, 1H), 6.92 (s, 1H), 7.02 (s, 1H), 7.4 (s, 1H), 7.53 (d, 1H), 7.65 (d, 1H), 8.68 (s, 1H); Mass Spectrum: M+H⁺ 472.

5 Example 3


4-benzofuran-7-ylamino-3-cyano-6,7-dimethoxyquinoline hydrochloride salt

A mixture of 4-chloro-3-cyano-6,7-dimethoxyquinoline (0.2 g), 7-aminobenzofuran (0.113 g) and n-propanol (15 ml) was stirred and heated to 110°C for 3 hours. The yellow precipitate was isolated, washed in turn with n-propanol and diethyl ether and dried under
10 vacuum. There was thus obtained the title compound (0.175 g); NMR Spectrum: (DMSOd₆) 4.0 (s, 6H), 7.18 (s, 1H), 7.36 (t, 1H), 7.44 (d, 1H), 7.51 (s, 1H), 7.73 (d, 1H), 8.0 (s, 1H), 8.24 (s, 1H), 8.92 (s, 1H); Mass Spectrum : M+H⁺ 346.

Example 4

Using an analogous procedure to that described in Example 3, the appropriate
15 4-chloro-3-cyanoquinoline was reacted with the appropriate 7-aminobenzofuran to give the compounds described in Table II. Unless otherwise stated, each product was obtained as a hydrochloride salt.

Table II



- 70 -

Compound No. & Note	R ¹	R ²
[1]	hydroxy	hydrogen
[2]	3-chloropropoxy	hydrogen
[3]	4-chlorobutoxy	hydrogen

[1] The reactants were 4-chloro-3-cyano-7-hydroxy-6-methoxyquinoline and 7-aminobenzofuran. The product gave the following characterising data; NMR Spectrum: (DMSO-d₆) 4.01 (s, 3H), 7.09 (d, 1H), 7.37 (t, 1H), 7.44 (d, 1H), 7.51 (s, 1H), 7.73 (d, 1H), 8.01 (s, 1H), 8.26 (s, 1H), 8.9 (s, 1H); Mass Spectrum: M+H⁺ 332.

[2] The reactants were 4-chloro-7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline (containing some 4-chloro-7-(3-bromopropoxy)-3-cyano-6-methoxyquinoline) and 7-aminobenzofuran and the reaction mixture was heated to 110°C for 3 hours. The product gave the following characterising data; NMR Spectrum: (DMSO-d₆) 2.28–2.42 (m, 2H), 3.67–3.87 (m, 2H), 4.01 (s, 3H), 4.28–4.35 (m, 2H), 7.08 (d, 1H), 7.37 (t, 1H), 7.44 (d, 1H), 7.54 (s, 1H), 7.73 (d, 1H), 7.99 (d, 1H), 8.23 (s, 1H), 8.94 (s, 1H); Mass Spectrum: M+H⁺ 407 and 409, 452 and 454.

[3] The reactants were 4-chloro-7-(4-chlorobutoxy)-3-cyano-6-methoxyquinoline (J. Medicinal Chemistry, 2001, 44, 3965-3977) and 7-aminobenzofuran and the reaction mixture was heated to 100°C for 5 hours. The product gave the following characterising data NMR Spectrum: (DMSO-d₆) 1.95 (m, 4H), 3.75 (m, 2H), 4.0 (s, 3H), 4.23 (m, 2H), 7.08 (d, 1H), 7.36 (t, 1H), 7.45 (d, 1H), 7.56 (s, 1H), 7.73 (d, 1H), 7.99 (d, 1H), 8.30 (s, 1H), 8.93 (s, 1H), 11.46 (br s, 1H); Mass Spectrum: M+H⁺ 422 and 424.

Example 5

7-[3-(4-acetylpiperazin-1-yl)propoxy]-4-benzofuran-7-ylamino-3-cyano-6-methoxyquinoline

A mixture of 4-benzofuran-7-ylamino-7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline (0.3 g), 1-acetylpiperazine (0.27 g) and DMF (5 ml) was stirred and heated to 90°C for 4 hours. The mixture was evaporated and the residue was partitioned between methylene chloride and water. The organic phase was washed with water and with brine, dried over magnesium sulphate and evaporated. The resultant residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and

- 71 -

a saturated methanolic ammonia solution as eluent. There was thus obtained the title compound (0.205 g); NMR Spectrum: (DMSO_d₆) 1.92-2.01 (m, 5H), 2.33 (t, 2H), 2.39 (t, 2H), 2.45-2.52 (m, 2H), 3.42 (m, 4H), 3.92 (s, 3H), 4.21 (t, 2H), 7.01 (d, 1H), 7.27 (m, 2H), 7.32 (s, 1H), 7.58 (m, 1H), 7.86 (s, 1H), 7.94 (s, 1H), 8.38 (s, 1H), 9.72 (s, 1H); Mass


5 Spectrum: M+H⁺ 500.

Example 6

Using an analogous procedure to that described in Example 5, the appropriate 7-(ω-haloalkoxy)-3-cyanoquinoline was reacted with the appropriate amine or heterocycle to give the compounds described in Table III. Unless otherwise stated, each compound

10 described in Table III was obtained as a free base.

Table III



15

Compound No. & Note	R ¹	R ²
[1]	3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy	hydrogen
[2]	3-(1,1-dioxotetrahydro-4H-thiazin-4-yl)propoxy	hydrogen
[3]	4-(4-acetylpiperazin-1-yl)butoxy	hydrogen
[4]	4-(4-methylpiperazin-1-yl)butoxy	hydrogen
[5]	3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy	hydrogen
[6]	4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy	hydrogen
[7]	3-piperazin-1-ylpropoxy	4-methoxy
[8]	3-(4-hydroxypiperidin-1-yl)propoxy	4-methoxy

- 72 -

Notes

[1] 1-(2-Fluoroethyl)piperazine trifluoroacetate salt was used as the heterocycle reactant. Diisopropylethylamine was added to the reaction mixture as an additional reactant to neutralise the trifluoroacetate salt. The product gave the following characterising data; NMR

5 Spectrum: (DMSO_d₆) 1.96 (m, 2H), 2.3–2.7 (m, 12H), 3.93 (s, 3H), 4.2 (t, 2H), 4.42 (t, 1H), 4.59 (t, 1H), 7.0 (d, 1H), 7.25–7.34 (m, 3H), 7.56 (m, 1H), 7.84 (m, 1H), 7.92 (s, 1H), 8.37 (s, 1H), 9.71 (s, 1H); Mass Spectrum: M+H⁺ 504.

The 1-(2-fluoroethyl)piperazine trifluoroacetate salt used as a starting material was prepared as follows :-

10 A mixture of 1-(tert-butoxycarbonyl)piperazine (5 g), 1-bromo-2-fluoroethane (5.11 g), potassium carbonate (9.26 g) and acetonitrile (60 ml) was stirred and heated to 60°C for 4 hours. The reaction mixture was cooled to ambient temperature and filtered and the filtrate was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of isohexane and ethyl acetate as eluent. There was thus obtained
15 4-(tert-butoxycarbonyl)-1-(2-fluoroethyl)piperazine as a solid (3.7 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 1.37 (s, 9H), 2.34–2.4 (m, 4H), 2.56 (t, 1H), 2.67 (t, 1H), 3.25–3.34 (m, 4H), 4.42 (t, 1H), 4.58 (t, 1H).

Trifluoroacetic acid (20 ml) was added to a mixture of 4-(tert-butoxycarbonyl)-1-(2-fluoroethyl)piperazine (3.7 g), triethylsilane (8 ml) and methylene chloride (100 ml) and
20 the resultant mixture was stirred at ambient temperature for 1.5 hours. The mixture was evaporated and the residue was triturated under diethyl ether. The solid so obtained was isolated, washed with diethyl ether and dried. There was thus obtained
1-(2-fluoroethyl)piperazine trifluoroacetic acid salt as a solid (6.0 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D) 3.0–3.31 (m, 10H), 4.59 (m, 1H), 4.75 (m, 1H).

25 [2] 1,1-Dioxotetrahydro-4H-thiazine was used as the heterocycle reactant. The material obtained after chromatographic purification was dissolved in methylene chloride and a solution of hydrogen chloride in diethyl ether (1M) was added. The resultant solid was washed with diethyl ether and dried. The product so obtained was the dihydrochloride salt which gave the following characterising data; NMR Spectrum: (DMSO_d₆ and CF₃CO₂D) 2.33
30 (m, 2H), 3.4 (m, 2H), 3.6–3.81 (m, 8H), 4.0 (s, 3H), 4.32 (t, 2H), 7.08 (d, 1H), 7.35 (t, 1H), 7.44 (d, 1H), 7.49 (s, 1H), 7.72 (d, 1H), 7.96 (d, 1H), 8.19 (s, 1H), 8.94 (s, 1H); Mass Spectrum: M+H⁺ 507.

- 73 -

[3] The reactants were 4-benzofuran-7-ylamino-7-(4-chlorobutoxy)-3-cyano-6-methoxyquinoline hydrochloride and 1-acetylpiperazine and the reaction solvent was n-propanol. The reaction mixture was heated to 90°C for 18 hours. The resultant mixture was partitioned between ethyl acetate and 1N aqueous sodium hydroxide solution. The organic layer was washed with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a saturated methanolic ammonia solution as eluent. The product so obtained gave the following characterising data; NMR Spectrum: (CDCl₃) 1.9 (m, 4H), 2.0 (s, 3H), 2.8-3.2 (m, 5H), 3.45 (m, 2H), 3.55 (m, 1H), 3.9-4.0 (m, 1H), 4.0 (s, 3H), 4.2 (m, 2H), 4.35 (m, 1H), 7.05 (s, 1H), 7.3 (t, 1H), 7.45 (d, 1H), 7.6 (s, 1H), 7.7 (d, 1H), 8.0 (d, 1H), 8.4 (s, 1H), 8.9 (s, 1H), 11.2 (br s, 1H), 11.7 (br s, 1H); Mass Spectrum: M+H⁺ 514.

[4] The reactants were 4-benzofuran-7-ylamino-7-(4-chlorobutoxy)-3-cyano-6-methoxyquinoline hydrochloride and 1-methylpiperazine and the reaction solvent was n-propanol. The reaction mixture was heated to 90°C for 18 hours. The resultant mixture was partitioned between ethyl acetate and 1N aqueous sodium hydroxide solution. The organic layer was washed with brine, dried over magnesium sulphate and evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a saturated methanolic ammonia solution as eluent. The product so obtained gave the following characterising data; NMR Spectrum: (CDCl₃) 1.9 (m, 4H), 2.8 (s, 3H), 3.15-3.8 (m, 10H), 4.0 (s, 3H), 4.2 (m, 2H), 7.05 (s, 1H), 7.35 (t, 1H), 7.45 (d, 1H), 7.6 (s, 1H), 7.7 (d, 1H), 8.0 (s, 1H), 8.35 (s, 1H), 8.9 (s, 1H), 11.5 (br s, 1H), 12.0 (br s, 2H); Mass Spectrum: M+H⁺ 486.

[5] 1,2,3,6-Tetrahydropyridine was used as the heterocycle reactant and the reaction solvent was 2-methoxyethanol. The reaction mixture was heated to 105°C for 2 hours. The product gave the following characterising data; NMR Spectrum: (CDCl₃) 2.15 (m, 2H), 2.19 (m, 2H), 2.64 (m, 4H), 3.0 (t, 2H), 3.52 (s, 3H), 4.25 (t, 2H), 5.67 (m, 1H), 5.76 (m, 1H), 6.84 (d, 1H), 6.89 (s, 1H), 7.01 (t, 1H), 7.2 (t, 1H), 7.38 (s, 1H), 7.45 (d, 1H), 7.6 (d, 1H), 8.65 (s, 1H); Mass Spectrum: M+H⁺ 455.

[6] 1,2,3,6-Tetrahydropyridine was used as the heterocycle reactant and the reaction solvent was 2-methoxyethanol. The reaction mixture was heated to 105°C for 4 hours. The product gave the following characterising data; NMR Spectrum: (CDCl₃) 1.73 (m, 2H), 1.94 (m, 2H), 2.17 (m, 2H), 2.47 (m, 2H), 2.56 (t, 2H), 2.96 (m, 2H), 3.52 (s, 3H), 4.17 (t, 2H),

- 74 -

5.65 (m, 1H), 5.74 (m, 1H), 6.82 (d, 1H), 6.95 (s, 1H), 7.0 (d, 1H), 7.19 (t, 1H), 7.26 (s, 1H), 7.34 (s, 1H), 7.45 (m, 1H), 7.57 (d, 1H), 8.62 (s, 1H); Mass Spectrum: $M+H^+$ 469.

[7] Piperazine was used as the amine reactant and the reaction solvent was

2-methoxyethanol. The reaction mixture was heated to 100°C for 3 hours. The product gave

5 the following characterising data; NMR Spectrum: (DMSO_d₆) 1.96 (m, 2H), 2.32 (m, 4H), 2.44 (t, 2H), 2.7 (m, 4H), 3.95 (s, 3H), 3.96 (s, 3H), 4.21 (t, 2H), 6.85 (d, 1H), 7.0 (d, 1H), 7.27 (d, 1H), 7.31 (s, 1H), 7.88 (m, 2H), 8.31 (s, 1H), 9.6 (br s, 1H); Mass Spectrum: $M+H^+$ 488.

[8] 4-Hydroxypiperidine was used as the amine reactant and the reaction solvent was

10 2-methoxyethanol. The reaction mixture was heated to 100°C for 6 hours. The product gave

the following characterising data; NMR Spectrum: (DMSO_d₆) 1.35-1.5 (m, 2H), 1.7-1.80 (m, 2H), 1.97 (m, 2H), 2.09 (m, 2H), 2.49 (m, 2H), 2.76 (m, 2H), 3.47 (m, 1H), 3.95 (s, 3H), 3.96 (s, 3H), 4.2 (t, 2H), 4.52 (s, 1H), 6.85 (d, 1H), 7.0 (s, 1H), 7.28 (d, 1H), 7.31 (s, 1H), 7.88 (m, 2H), 8.32 (s, 1H), 9.6 (s, 1H); Mass Spectrum: $M+H^+$ 503.

15 Example 7

4-benzofuran-7-ylamino-3-cyano-6-methoxy-7-[3-(4-prop-2-ynyl)piperazin-1-yl]propoxy]quinoline

A mixture of 4-benzofuran-7-ylamino-7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline (0.3 g), 1-(2-propynyl)piperazine trifluoroacetate salt (International
20 Patent Application WO 98/01164; 0.382 g), diisopropylethylamine (0.541 g) and 2-methoxyethanol (12 ml) was stirred and heated to 100°C for 4 hours. The mixture was evaporated and the resultant residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a saturated methanolic ammonia solution as eluent. There was thus obtained the title compound (0.125 g); NMR Spectrum:
25 (DMSO_d₆ and CF₃CO₂D) 1.98-2.09 (m, 2H), 2.52-2.59 (m, 4H), 2.64-2.76 (m, 6H), 3.11 (m, 1H), 3.29 (d, 2H), 3.92 (s, 3H), 4.2 (t, 2H), 7.0 (d, 1H), 7.24-7.3 (m, 2H), 7.34 (s, 1H), 7.56 (m, 1H), 7.86 (s, 1H), 7.9 (s, 1H), 8.37 (s, 1H); Mass Spectrum: $M+H^+$ 496.

Example 8

4-benzofuran-7-ylamino-3-cyano-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]quinoline

30 hydrochloride salt

Diisopropyl azodicarboxylate (0.414 g) was added dropwise to a stirred suspension of 4-benzofuran-7-ylamino-3-cyano-7-hydroxy-6-methoxyquinoline (0.565 g),

- 75 -

2-(2-methoxyethoxy)ethanol (0.307 g), triphenylphosphine (0.627 g) and methylene chloride (30 ml). The mixture was stirred at ambient temperature for 3 hours. The mixture was evaporated and the residue was purified by column chromatography on silica eluting with increasingly polar mixtures of ethyl acetate and methanol as eluent. The material so obtained
5 was dissolved in methylene chloride and a solution of hydrogen chloride in diethyl ether (1M, 2 ml) was added. The resultant solid was washed with diethyl ether and dried. There was thus obtained the title compound as a solid (0.19 g); NMR Spectrum: (DMSO_d₆) 3.26 (s, 3H), 3.48 (m, 2H), 3.61 (m, 2H), 3.83 (m, 2H), 3.94 (s, 3H), 4.28 (t, 2H), 7.01 (d, 1H), 7.25–7.31 (m, 2H), 7.36 (s, 1H), 7.58 (m, 1H), 7.86 (s, 1H), 7.92 (s, 1H), 8.13 (s, 1H), 8.39 (s, 1H), 9.74 (s,
10 1H); Mass Spectrum: M+H⁺ 434.

Example 9

3-cyano-4-(4-cyanobenzofuran-7-ylamino)-6,7-dimethoxyquinoline

Tris(dibenzylideneacetone)dipalladium (0.037 g) was added to a mixture of 3-cyano-4-(4-iodobenzofuran-7-ylamino)-6,7-dimethoxyquinoline (0.25 g), zinc cyanide
15 (0.064 g), diphenylphosphinoferrocene (0.038 g), zinc powder (0.014 g) and DMA (20 ml) and the resultant mixture was stirred and heated to 110°C for 2 hours. The mixture was cooled to ambient temperature and partitioned between methylene chloride and water. The organic layer was washed with water, dried over magnesium sulphate and evaporated and the residue was purified by column chromatography on silica using increasingly polar mixtures of
20 isohexane and ethyl acetate as eluent. There was thus obtained the title compound as a solid (0.123 g); NMR Spectrum: (DMSO_d₆) 3.93 (s, 3H), 3.99 (s, 3H), 7.2 (d, 1H), 7.29 (d, 1H), 7.43 (s, 1H), 7.76 (s, 1H), 7.79 (d, 1H), 8.19 (d, 1H), 8.62 (s, 1H), 10.11 (br s, 1H); Mass Spectrum: M+H⁺ 371.

Example 10

4-(benzofuran-7-ylamino)-3-cyano-5-(N-methylpiperidin-4-yloxy)quinoline dihydrochloride salt

A mixture of 4-chloro-3-cyano-5-(N-methylpiperidin-4-yloxy)quinoline (0.15 g), 7-aminobenzofuran (0.073 g) and DMF (5 ml) was stirred in an ice-bath. Sodium hexamethyldisilazane (1M solution in THF; 1 ml) was added and the mixture was allowed to
30 warm to ambient temperature over 1 hour. The solvent was evaporated and the residue was purified by column chromatography on silica using increasingly polar mixture of methylene chloride and methanol as eluent. The material so obtained was dissolved in ethanol (8 ml) and

- 76 -

2 equivalents of 1M hydrogen chloride in diethyl ether was added. The mixture was evaporated to give the title compound as a solid (0.131 g); NMR Spectrum: (DMSO_d₆, warmed to 120°C) 2.27 (m, 2H), 2.43 (m, 2H), 2.65 (s, 3H), 3.21 (m, 4H), 5.07 (m, 1H), 7.01 (d, 1H), 7.31 (t, 1H), 7.4 (m, 2H), 7.65 (m, 2H), 7.81 (t, 1H), 7.94 (d, 1H), 8.57 (s, 1H), 10.27 (br s, 1H); Mass Spectrum: M+H⁺ 399.

The 4-chloro-3-cyano-5-(N-methylpiperidin-4-yloxy)quinoline used as a starting material was prepared as follows :-

Dimethyl sulphate (2.38 ml) was added dropwise to a stirred mixture of 6-fluoroanthranilic acid (3.9 g), potassium carbonate (7.64 g) and DMF (100 ml) which had been cooled to 0°C. The reaction was allowed to warm to ambient temperature and was stirred for 2 hours. The mixture was evaporated and the resulting oil was partitioned between methylene chloride and evaporated. There was thus obtained methyl 6-fluoroanthranilate (4.78 g); NMR Spectrum: (DMSO_d₆) 3.8 (s, 3H), 6.3 (m, 1H), 6.6 (m, 3H), 7.2 (m, 1H); Mass Spectrum: M+H⁺ 170.

A mixture of the material so obtained and dimethylformamide dimethyl acetal (20 ml) was stirred and heated to 115°C for 12 hours. The reaction mixture was allowed to cool to ambient temperature and the excess of dimethylformamide dimethyl acetal was evaporated. Methylene chloride (100 ml) was added to the residual oil and the mixture was filtered. The filtrate was evaporated to provide an orange oil (4.11 g, 71%) which was used without further purification; NMR Spectrum: (DMSO_d₆) 2.8 (s, 3H), 3.0 (s, 3H), 3.7 (s, 3H), 6.8 (m, 2H), 7.3 (m, 1H), 7.8 (s, 1H); Mass Spectrum: M+H⁺ 225.

Whilst maintaining a reaction mixture temperature of less than -70°C, a solution in THF (6.5 ml) of a portion (0.8 g) of the material so obtained was added dropwise to the mixture obtained when a solution of acetonitrile (0.37 g) in THF (5 ml) was added dropwise to a solution of *n*-butyllithium (2.5M in hexane; 2.98 ml) in THF (3.5 ml) that had been cooled to -78°C. The resultant reaction mixture was stirred at -78°C for 2 hours and at ambient temperature for a further 2 hours. The mixture was cooled to -78°C and acetic acid (3 ml) was added. The reaction mixture was stirred vigorously and allowed to warm to ambient temperature over 12 hours. Water (10 ml) was added and the resultant white solid was isolated and dried. There was thus obtained 3-cyano-5-fluoro-4-hydroxyquinoline (0.43 g); NMR Spectrum: (DMSO_d₆) 7.1 (m, 1H), 7.4 (d, 1H), 7.7 (m, 1H), 8.6 (s, 1H); Mass Spectrum: M+H⁺ 189.

- 77 -

4-Hydroxy-N-methylpiperidine (6.08 g) was added to a stirred slurry of sodium hydride (60% dispersion in oil; 4.23 g) in DMA (150 ml) and the mixture was stirred at ambient temperature for 10 minutes. 3-Cyano-5-fluoro-4-hydroxyquinoline (6 g) was added in portions and the resultant mixture was stirred and heated to 80°C for 6 hours. The solvent was evaporated and the residue was partitioned between water and diethyl ether. The aqueous layer was neutralised by the addition of acetic acid and the resultant mixture was evaporated. Ethanol and toluene were added to the residue and the solution was re-evaporated. This process was repeated using toluene alone. There was thus obtained 3-cyano-4-hydroxy-5-(N-methylpiperidin-4-yloxy)quinoline as a white solid (8 g).

10 A mixture of the material so obtained, phosphoryl chloride (50 ml) and acetonitrile (200 ml) was stirred and heated to 95°C for 3 hours. The mixture was allowed to cool to ambient temperature. The solvent was evaporated and the gum so obtained was treated with a mixture of a concentrated aqueous ammonium hydroxide solution and ice. The mixture was allowed to warm to ambient temperature and the solid so obtained was collected, washed with water and dried. There was thus obtained 4-chloro-3-cyano-5-(N-methylpiperidin-4-yloxy)quinoline (8.07 g); NMR Spectrum: (DMSO_d₆) 1.9 (m, 2H), 2.06 (m, 2H), 2.27 (s, 3H), 2.36 (m, 2H), 2.71 (m, 2H), 4.72 (m, 1H), 7.35 (d, 1H), 7.69 (d, 1H), 7.88 (t, 1H), 8.99 (s, 1H); Mass Spectrum: M+H⁺ 302.

Example 11

20 **4-(benzofuran-7-ylamino)-3-cyano-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline dihydrochloride salt**

A solution of hydrogen chloride in diethyl ether (1M, 0.36 ml) was added to a mixture of 4-chloro-3-cyano-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline (0.12 g), 7-aminobenzofuran (0.053 g) and n-propanol (8 ml) and the resultant mixture was stirred and heated to reflux for 6 hours. The mixture was cooled to ambient temperature and the precipitate was isolated and washed with n-propanol. There was thus obtained the title compound as a white solid (0.136 g); NMR Spectrum: (DMSO_d₆ and CD₃CO₂D; warmed to 120°C) 2.21 (m, 2H), 2.38 (m, 2H), 2.7 (s, 3H), 3.23 (m, 4H), 3.99 (s, 3H), 5.11 (m, 1H), 7.05 (d, 2H), 7.17 (s, 1H), 7.34 (t, 1H), 7.43 (d, 1H), 7.68 (d, 1H), 7.96 (s, 1H), 8.7 (s, 1H); Mass Spectrum: M+H⁺ 429.

The 4-chloro-3-cyano-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline used as a starting material was prepared as follows :-

- 78 -

A mixture of 3,5-difluoroaniline (32.25 g), ethyl 2-cyano-3-ethoxyacrylate (42.25 g) and ethanol (200 ml) was heated to reflux for 2 hours. The mixture was allowed to cool to ambient temperature and the precipitate was isolated and washed with a small amount of ethanol. There was thus obtained ethyl 2-cyano-3-(3,5-difluoroanilino)acrylate as white
5 needles (58 g); NMR Spectrum: (DMSO_d₆) 1.28 (m, 3H), 4.23 (m, 2H), 6.98–7.42 (m, 3H), 8.44 (m, 1H), 10.8 (m, 1H); Mass Spectrum: M+H⁺ 253.

Ethyl 2-cyano-3-(3,5-difluoroanilino)acrylate (12.5 g) was added portionwise over 10 minutes to di(ethylene glycol) dibutyl ether (100 ml) that had been heated to reflux. The resultant mixture was heated to reflux for a further 30 minutes. The mixture was allowed to
10 cool to ambient temperature and the precipitate was collected and washed with ethyl acetate. There was thus obtained 3-cyano-5,7-difluoro-4-hydroxyquinoline as a solid (4.24 g); NMR Spectrum: (DMSO_d₆) 7.21 (m, 1H), 7.3 (m, 1H), 8.72 (s, 1H), 12.86 (br, 1H); Mass Spectrum: M+H⁺ 207.

A mixture of 3-cyano-5,7-difluoro-4-hydroxyquinoline (4.12 g), N-methylpiperidin-4-
15 ol (2.6 g), potassium tert-butoxide (6.72 g) and THF (250 ml) was stirred and heated at 60°C for 2 hours. The mixture was acidified to pH6 by the addition of glacial acetic acid and the resultant mixture was evaporated. The residue was purified by column chromatography on silica using increasingly polar mixtures of methylene chloride and a saturated methanolic ammonia solution as eluent. There was thus obtained 3-cyano-7-fluoro-4-hydroxy-
20 5-(N-methylpiperidin-4-yloxy)quinoline as a foam (3.55 g); NMR Spectrum: (DMSO_d₆) 1.77 (m, 2H), 1.92 (m, 2H), 2.3 (s, 3H), 2.43 (m, 2H), 2.81 (m, 2H), 4.55 (m, 1H), 6.81 (m, 2H), 8.4 (s, 1H); Mass Spectrum: M+H⁺ 302.

A mixture of a portion (0.6 g) of the material so obtained, methanol (0.4 ml), potassium tert-butoxide (1M solution in THF; 10 ml) and DMSO (20 ml) was stirred and
25 heated at 70°C for 16 hours. The solution was cooled to ambient temperature and diluted with water (100 ml). The mixture was acidified to pH6 by the addition of dilute aqueous hydrochloric acid and filtered. The filtrate was passed through a cation exchange cartridge (Waters Oasis MCX 6 g) using water (200 ml), a 1:1 mixture (200 ml) of methanol and water and then methanol (200 ml) as eluent. The product was eluted off the column with methanol
30 containing triethylamine (1%). There was thus obtained 3-cyano-4-hydroxy-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline as a white solid (0.46 g); NMR Spectrum: (DMSO_d₆) 1.67

- 79 -

(m, 2H), 1.83 (m, 2H), 2.12 (m, 2H), 2.15 (s, 3H), 2.64 (m, 2H), 4.31 (m, 1H), 6.31 (d, 1H), 6.56 (d, 1H), 8.16 (s, 1H); Mass Spectrum: $M+H^+$ 314.

A mixture of a portion (0.313 g) of the material so obtained, phosphoryl chloride (1.8 ml) and acetonitrile (10 ml) was stirred and heated to reflux for 20 hours. The mixture was cooled to ambient temperature and evaporated. The gum so obtained was treated with a mixture of a concentrated aqueous ammonium hydroxide solution (25 ml) and ice. The mixture was allowed to warm to ambient temperature and the solid so obtained was collected and dried overnight. There was thus obtained 4-chloro-3-cyano-7-methoxy-5-(N-methylpiperidin-4-yloxy)quinoline as a white solid (0.225 g); NMR Spectrum: (DMSO_d₆) 1.8 (m, 2H), 1.98 (m, 2H), 2.18 (s, 3H), 2.27 (m, 2H), 2.58 (m, 2H), 3.94 (s, 3H), 4.72 (m, 1H), 6.92 (d, 1H), 7.09 (d, 1H), 8.93 (s, 1H); Mass Spectrum: $M+H^+$ 332.

Example 12

4-(benzofuran-7-ylamino)-3-cyano-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinoline dihydrochloride salt

A solution of hydrogen chloride in diethyl ether (1M, 0.37 ml) was added to a mixture of 4-chloro-3-cyano-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinoline (0.16 g), 7-aminobenzofuran (0.073 g) and n-propanol (8 ml) and the resultant mixture was stirred and heated to reflux for 2 hours. The mixture was cooled to ambient temperature and the precipitate was isolated and washed with n-propanol. There was thus obtained the title compound as a white solid (0.159 g); NMR Spectrum: (DMSO_d₆; warmed to 120°C) 1.86 (m, 2H), 2.11 (m, 2H), 2.32 (m, 2H), 3.1 (m, 2H), 3.33 (m, 2H), 3.49 (m, 4H), 3.80 (m, 2H), 3.88 (m, 2H), 3.96 (m, 2H), 4.33 (t, 2H), 5.13 (m, 1H), 7.09 (d, 2H), 7.15 (d, 1H), 7.35 (t, 1H), 7.46 (d, 1H), 7.72 (d, 1H), 8.04 (d, 1H), 8.84 (s, 1H), 10.84 (s, 1H), 11.45 (s, 1H); Mass Spectrum: $M+H^+$ 529.

The 4-chloro-3-cyano-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinoline used as a starting material was prepared as follows :-

A mixture of 3-cyano-5,7-difluoro-4-hydroxyquinoline (2.06 g), 4-hydroxytetrahydropyran (1.02 g), potassium tert-butoxide (1M solution in THF; 30 ml) and THF (100 ml) was stirred and heated to 60°C for 1.5 hours. The mixture was acidified to pH6 by the addition of glacial acetic acid and the resultant mixture was evaporated. Aqueous sodium hydroxide solution (2M, 20 ml) was added to the residue and the mixture was filtered. The filtrate was acidified to pH5 by the addition of glacial acetic acid and the resultant oily

- 80 -

precipitate was allowed to stand for 3 days when it had solidified fully. The solid was collected, washed with water and dried. There was thus obtained 3-cyano-7-fluoro-4-hydroxy-5-tetrahydropyran-4-yloxyquinoline (1.8 g); NMR Spectrum: (DMSO_d₆) 1.67 (m, 2H), 1.92 (m, 2H), 3.5 (m, 2H), 3.91 (m, 2H), 4.76 (m, 1H), 6.81 (m, 1H), 6.94 (m, 1H), 8.52 (s, 1H); Mass Spectrum: M+H⁺ 289.

A mixture of a portion (0.864 g) of the material so obtained, 4-(3-hydroxypropyl)morpholine (Bull. Soc. Chim. Fr., 1962, 1117; 0.876 g), potassium tert-butoxide (1M solution in THF; 9 ml) in DMSO (30 ml) was stirred and heated to 60°C for 8 hours. The resultant mixture was cooled to ambient temperature and diluted with water (120 ml). The mixture was acidified to pH5 by the addition of glacial acetic acid and passed through a cation exchange cartridge (Waters Oasis MCX 6 g) using water (200 ml), a 1:1 mixture (200 ml) of methanol and water and then methanol (200 ml) as eluent. The product was eluted off the column with methanol containing triethylamine (1%). The material so obtained was purified further using column chromatography on silica using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 3-cyano-4-hydroxy-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinoline as a white solid (0.54 g); NMR Spectrum: (DMSO_d₆; warmed to 120°C) 1.73 (m, 2H), 1.91 (m, 4H), 2.39 (m, 4H), 2.45 (t, 2H), 3.49 (m, 2H), 3.58 (m, 4H), 3.95 (m, 2H), 4.1 (t, 2H), 4.64 (m, 1H), 6.46 (d, 1H), 6.6 (d, 1H), 8.24 (s, 1H); Mass Spectrum: M+H⁺ 414.

A mixture of a portion (0.5 g) of the material so obtained, phosphoryl chloride (2.5 ml) and acetonitrile (15 ml) was stirred and heated to reflux for 4 hours. The mixture was cooled to ambient temperature and evaporated. The gum so obtained was treated with a mixture of a concentrated aqueous ammonium hydroxide solution (25 ml) and ice. The mixture was allowed to warm to ambient temperature and the solid so obtained was collected and dried overnight. There was thus obtained 4-chloro-3-cyano-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinoline as a white solid (0.48 g); Mass Spectrum: M+H⁺ 432.

Example 13

Pharmaceutical composition

The following illustrates a representative pharmaceutical dosage form for use according to the invention (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:

- 81 -

(a)	Tablet I	mg/tablet
	Compound X.....	100
	Lactose Ph.Eur.....	182.75
	Croscarmellose sodium.....	12.0
5	Maize starch paste (5% w/v paste).....	2.25
	Magnesium stearate.....	3.0

Note

The above formulation may be obtained by conventional procedures well known in the
10 pharmaceutical art. The tablet may be enteric coated by conventional means, for example to
provide a coating of cellulose acetate phthalate.

15


20

25

30

CLAIMS


1. The use of a quinoline derivative of the Formula I



- wherein Z is an O, S, SO, SO₂, N(R²) or C(R²)₂ group, wherein each R² group, which may be
 5 the same or different, is hydrogen or (1-6C)alkyl;

m is 0, 1, 2, 3 or 4;

- each R¹ group, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy,
 10 (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino,
 15 N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :




- wherein X¹ is a direct bond or is selected from O, S, SO, SO₂, N(R⁴), CO, CH(OR⁴), CON(R⁴), N(R⁴)CO, SO₂N(R⁴), N(R⁴)SO₂, OC(R⁴)₂, SC(R⁴)₂ and N(R⁴)C(R⁴)₂, wherein R⁴ is
 20 hydrogen or (1-6C)alkyl, and Q¹ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or (R¹)_m is (1-3C)alkylenedioxy,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂,
 25 N(R⁵), CO, CH(OR⁵), CON(R⁵), N(R⁵)CO, SO₂N(R⁵), N(R⁵)SO₂, CH=CH and C≡C wherein

- 83 -


R⁵ is hydrogen or (1-6C)alkyl or, when the inserted group is N(R⁵), R⁵ may also be (2-6C)alkanoyl,

and wherein any CH₂=CH- or HC≡C- group within a R¹ substituent optionally bears at the terminal CH₂= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl and di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :



wherein X² is a direct bond or is selected from CO and N(R⁶)CO, wherein R⁶ is hydrogen or (1-6C)alkyl, and Q² is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X³ is a direct bond or is selected from O, S, SO, SO₂, N(R⁷), CO, CH(OR⁷), CON(R⁷), N(R⁷)CO, SO₂N(R⁷), N(R⁷)SO₂, C(R⁷)₂O, C(R⁷)₂S and N(R⁷)C(R⁷)₂, wherein R⁷ is hydrogen or (1-6C)alkyl, and Q³ is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R¹ optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,


- 84 -

N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl,

10 or from a group of the formula :




wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same
15 or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo or thioxo substituents;

n is 0, 1, 2 or 3; and


20 R^3 is halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphanyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-
25 (3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino and N-(1-6C)alkyl-(1-6C)alkanesulphonylamino, or from a group of the formula :



30 wherein X^6 is a direct bond or is selected from O and $N(R^{12})$, wherein R^{12} is hydrogen or (1-6C)alkyl, and R^{11} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl,

- 85 -


cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl, or from a group of the formula :



- wherein X^7 is a direct bond or is selected from O, S, SO, SO₂, N(R¹³), CO, CH(OR¹³),
 5 CON(R¹³), N(R¹³)CO, SO₂N(R¹³), N(R¹³)SO₂, C(R¹³)₂O, C(R¹³)₂S and N(R¹³)C(R¹³)₂,
 wherein R¹³ is hydrogen or (1-6C)alkyl, and Q⁵ is aryl, aryl-(1-6C)alkyl, heteroaryl,
 heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2
 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl,
 (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy, and any heterocyclyl group within Q⁵
 10 optionally bears 1 or 2 oxo or thioxo substituents,
 or a pharmaceutically-acceptable salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

- 15 2. The use of a quinoline derivative of the Formula I as claimed in claim 1 wherein m is 1 or 2, and each R¹ group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino and N-(1-6C)alkyl-
 20 (2-6C)alkanoylamino, or from a group of the formula :




- wherein X¹ is selected from O, N(R⁴), CON(R⁴), N(R⁴)CO and OC(R⁴)₂ wherein R⁴ is hydrogen or (1-6C)alkyl, and Q¹ is aryl, aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or X¹ is a direct bond and
 25 Q¹ is aryl-(1-6C)alkyl, cycloalkyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or heterocyclyl-(1-6C)alkyl,

- and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R¹ substituent are optionally separated by the insertion into the chain of a group selected from O, N(R⁵), CON(R⁵), N(R⁵)CO, CH=CH and C≡C wherein R⁵ is hydrogen or (1-6C)alkyl, or, when the
 30 inserted group is N(R⁵), R⁵ may also be (2-6C)alkanoyl,

and wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno groups or a substituent selected from hydroxy,


- 86 -

amino, (1-6C)alkoxy, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyloxy, (2-6C)alkanoylamino and N-(1-6C)alkyl-(2-6C)alkanoylamino, or from a group of the formula :



5 wherein X^3 is a direct bond or is selected from O, $N(R^6)$, $CON(R^7)$, $N(R^7)CO$ and $C(R^7)_2O$, wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from
10 halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (1-6C)alkylsulphonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl and (2-6C)alkanoyl, or optionally bears 1 substituent selected from a group of the formula :



15 wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl or (1-6C)alkoxycarbonylamino-(1-6C)alkyl, and from a group of the formula :

20 $-X^5-Q^4$

wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy,

25 and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents,

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

30 3. The use of a quinoline derivative of the Formula I as claimed in claim 1 wherein R^1 substituents may only be located at the 5-, 6- and/or 7-positions on the quinoline ring,

- 87 -

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

4. The use of a quinoline derivative of the Formula I as claimed in claim 1 wherein :

5 Z is NH;

m is 2 and the first R¹ group is a 6-methoxy group and the second R¹ group is located at the 7-position and is selected from methoxy, 3-morpholinopropoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy, 4-(1,2,3,6-tetrahydropyridin-1-yl)butoxy, 3-(4-hydroxypiperidin-1-yl)propoxy, 3-piperazin-1-ylpropoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-(4-methylpiperazin-1-yl)butoxy, 3-(4-prop-2-ynylpiperazin-1-yl)propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 4-(4-acetylpiperazin-1-yl)butoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, and 2-(2-methoxyethoxy)ethoxy; and n is 0 or n is 1 and the R³ group, if present, is located at the 3-, 4- or 6-position of the benzofuranyl group and is selected from chloro, bromo, iodo and methoxy, or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

20 5. The use of a quinoline derivative of the Formula I wherein :

Z is NH;

m is 1 and the R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy and N-methylpiperidin-4-yloxy, or m is 2 and the first R¹ group is located at the 5-position and is selected from tetrahydropyran-4-yloxy and N-methylpiperidin-4-yloxy, and the second R¹ group is located at the 7-position and is selected from methoxy and 3-morpholinopropoxy; and n is 0,

or a pharmaceutically-acceptable acid-addition salt thereof;

in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

- 88 -

6. The use of a quinoline derivative of the Formula I as claimed in claim 1 selected from:-

- 7-[3-(4-acetylpiperazin-1-yl)propoxy]-4-benzofuran-7-ylamino-3-cyano-6-methoxyquinoline;
- 5 4-benzofuran-7-ylamino-7-[3-(1,1-dioxotetrahydro-4H-thiazin-4-yl)propoxy]-3-cyano-6-methoxyquinoline;
- 4-benzofuran-7-ylamino-3-cyano-7-[3-(1,2,3,6-tetrahydropyridin-1-yl)propoxy]-6-methoxyquinoline;
- 4-benzofuran-7-ylamino-7-[3-(1,2,3,6-tetrahydropyridin-1-yl)butoxy]-3-cyano-10 6-methoxyquinoline;
- 4-benzofuran-7-ylamino-3-cyano-6-methoxy-7-(3-morpholinopropoxy)quinoline;
- 3-cyano-4-(4-methoxybenzofuran-7-ylamino)-6,7-dimethoxyquinoline;
- 3-cyano-4-(4-cyanobenzofuran-7-ylamino)-6,7-dimethoxyquinoline;
- 4-benzofuran-7-ylamino-3-cyano-6-methoxy-7-[2-(2-ethoxyethoxy)ethoxy]-15 quinoline;
- 3-cyano-6-methoxy-4-(4-methoxybenzofuran-7-ylamino)-7-(3-morpholinopropoxy)quinoline;
- 3-cyano-7-[3-(4-methylpiperazin-1-yl)propoxy]-6-methoxy-4-(4-methoxybenzofuran-7-ylamino)quinoline;
- 20 3-cyano-7-[3-(4-hydroxypiperidin-1-yl)propoxy]-6-methoxy-4-(4-methoxybenzofuran-7-ylamino)quinoline;
- 4-benzofuran-7-ylamino-3-cyano-7-(3-morpholinopropoxy)-5-tetrahydropyran-4-yloxyquinoline; and
- 3-cyano-4-[4-iodobenzofuran-7-ylamino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-6-methoxy,
- 25 or a pharmaceutically-acceptable acid-addition salt thereof;
- in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

30 7. A method for producing an anti-proliferative effect by the containment and/or treatment of solid tumour disease in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a quinoline derivative of the

- 89 -

Formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 6.

8. The use of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 6 in the manufacture of a medicament for use in the prevention or treatment of tumours which are sensitive to inhibition of MEK enzymes that are involved in the MAPK pathway.

9. A method for the prevention or treatment of tumours which are sensitive to inhibition of MEK enzymes that are involved in the MAPK pathway which comprises administering to a warm-blooded animal in need of treatment an effective amount of a quinoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 6.

10. A pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 6 in association with a pharmaceutically acceptable diluent or carrier for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/05497

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4709 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 18761 A (AMERICAN CYANAMID CO) 6 April 2000 (2000-04-06) cited in the application the whole document page 1, line 1 -page 5, line 17 page 7, line 18 -page 19, line 8 page 16, line 11 page 61, line 1 -page 65, line 51 page 67, line 10 -page 71, line 10 claims 1-3,7,12,13 -----	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

17 March 2003

Date of mailing of the international search report

27/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Economou, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 02/05497

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0018761	A	06-04-2000	
		AU 6159399 A	17-04-2000
		BR 9914167 A	19-06-2001
		CA 2344169 A1	06-04-2000
		CN 1320121 T	31-10-2001
		CZ 20011038 A3	12-09-2001
		EP 1117659 A1	25-07-2001
		HU 0103520 A2	28-02-2002
		JP 2002525369 T	13-08-2002
		NO 20011575 A	28-05-2001
		PL 346934 A1	11-03-2002
		SK 4132001 A3	07-01-2002
		WO 0018761 A1	06-04-2000